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Supplement introduction
approach, manufacturers of technologies, which 
are, in general, pharmaceuticals close to the time 
of launch, submit a dossier of evidence aiming to 
demonstrate effectiveness and cost-effectiveness. 
The independent academic input to NICE’s 
process, which continues to be supported by the 
TAR centres around the UK under contract to the 
HTA programme, is to scrutinise, critique and 
explore this dossier of evidence.
The papers included in this Supplement report 
on this HTA programme funded work, and we 
hope that the summaries of the work carried out 
to inform the development of NICE guidance for 
these technologies will be of interest and value to 
readers. 
Further details of each of the NICE Appraisals are 
available on the NICE website (www. nice.org.uk) 
and we welcome comments on the summaries via 
the HTA website (www.hta.ac.uk/correspond).
Prof. Tom Walley 
Director, NIHR HTA programme 
Editor-In-Chief, Health Technology Assessment
Prof. Ken Stein 
Chair, Editorial Board, Health Technology Assessment
W
elcome to the second Supplement to the 
Health Technology Assessment journal series. 
The series is now over 10 years old and has 
published more than 400 titles, covering a wide 
range of health technologies in a diverse set of 
applications. In general, the series publishes each 
technology assessment as a separate issue within 
each annual volume. 
The Supplements depart from that format by 
containing a series of shorter articles. These are all 
products from a ‘call-off contract’, which the HTA 
programme holds with a range of academic centres 
around the UK, at the universities of Aberdeen, 
Birmingham, Exeter, Liverpool, Sheffield, 
Southampton and York. These centres are retained 
to provide a highly responsive resource, which 
meets the needs of national policy makers, notably 
the National Institute for Health and Clinical 
Excellence (NICE).
Until recently, these HTA Technology Assessment 
Review (TAR) centres provided academic input to 
policy making through independent analyses of 
the impact and value of health technologies. As 
many readers will be aware, the perception that 
the advice NICE provides to the NHS could be 
made more timely has led to the development of 
the ‘Single Technology Appraisal’ process. In this Health Technology Assessment 2009; Vol. 13: Suppl. 2
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Abstract
This paper presents a summary of the evidence 
review group (ERG) report into the evidence for 
the clinical effectiveness and cost-effectiveness 
of gemcitabine with paclitaxel for the first-line 
treatment of metastatic breast cancer (MBC) in 
patients who have already received chemotherapy 
treatment with an anthracycline, compared 
with current standard of care, based upon the 
manufacturer’s submission to the National Institute 
for Health and Clinical Excellence (NICE) as 
part of the single technology appraisal (STA) 
process. The clinical evidence for gemcitabine as 
a treatment for MBC comes from the unpublished 
JHQG trial (some data commercial-in-confidence): 
overall survival was 3 months longer for the 
gemcitabine/paclitaxel arm (18.5 months) than 
for the paclitaxel arm (15.8 months) (p = 0.0489); 
gemcitabine/paclitaxel also improved tumour 
response and time to documented progression of 
disease compared with paclitaxel monotherapy, but 
haematological serious adverse events were more 
common. In the absence of any formal methods 
of indirect comparison there is insufficient robust 
evidence to compare the relative effectiveness of 
gemcitabine/paclitaxel with docetaxel monotherapy 
or docetaxel/capecitabine combination therapy. 
The manufacturers used a Markov state transition 
model to estimate the effect of treatment with five 
different chemotherapy regimes, adopting a 3-year 
time horizon with docetaxel monotherapy as the 
comparator. Health state utilities for different 
stages of disease progression and for patients 
experiencing treatment-related toxicity are used to 
derive quality-adjusted life expectancy with each 
treatment. The base-case cost-effectiveness estimate 
for gemcitabine/paclitaxel versus docetaxel is 
£17,168 per quality-adjusted life-year (QALY). 
HTA 06/16/01
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The research reported in this article of the journal 
supplement was commissioned and funded by the 
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Appraisal Committee’s review.
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sections are clearly marked in the report.
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When longer survival with docetaxel is assumed 
in a sensitivity analysis, the incremental cost-
effectiveness ratio (ICER) is £30,000 per QALY. 
Probabilistic sensitivity analysis estimates a 70% 
probability of gemcitabine/paclitaxel being cost-
effective relative to docetaxel at a willingness-to-
pay threshold of £35,000. There is considerable 
uncertainty over the results because of the lack 
of formal quality assessment or assessment of the 
comparability of the 15 trials included in the input 
data, and the questionable validity of the indirect 
comparison method adopted. An illustrative 
analysis using a different method for indirect 
comparison carried out by the ERG produces 
an ICER of £45,811 per QALY for gemcitabine/
paclitaxel versus docetaxel. The guidance issued 
by NICE in November 2006 as a result of the 
STA states that gemcitabine in combination 
with paclitaxel, within its licensed indication, is 
recommended as an option for the treatment 
of MBC only when docetaxel monotherapy or 
docetaxel plus capecitabine is also considered 
appropriate.
Introduction
The National Institute for Health and Clinical 
Excellence (NICE) is an independent organisation 
within the NHS that is responsible for providing 
national guidance on the treatment and care of 
people using the NHS in England and Wales. 
One of the responsibilities of NICE is to provide 
guidance to the NHS on the use of selected new 
and established health technologies, based on an 
appraisal of those technologies.
NICE’s single technology appraisal (STA) process 
is specifically designed for the appraisal of a single 
product, device or other technology, with a single 
indication, for which most of the relevant evidence 
lies with one manufacturer or sponsor.1 Typically, 
it is used for new pharmaceutical products close 
to launch. The principal evidence for an STA is 
derived from a submission by the manufacturer/
sponsor of the technology. In addition, a report 
reviewing the evidence submission is submitted 
by the evidence review group (ERG), an external 
organisation independent of NICE. This paper 
presents a summary of the ERG report for the 
STA of gemcitabine for advanced metastatic breast 
cancer.2
Description of the 
underlying health problem
Breast cancer is classified into four clinical stages. 
Stages I and II are known as primary or early 
breast cancer, and stages III and IV represent 
advanced breast cancer. Stage IV is metastatic 
disease, characterised by the spread of secondary 
tumours to distant sites. A small proportion of 
incident breast cancers present as stage IV, i.e. they 
have overt metastases at the time of diagnosis. 
Approximately 40% of patients treated for early 
breast cancer will relapse and develop metastatic 
breast cancer (MBC). Patients who present with 
stage IV disease at first diagnosis are described by 
the manufacturer as being unsuitable for treatment 
with gemcitabine as they will not have received 
prior anthracycline therapy.
Scope of the ERG report
The submission’s scope is the use of gemcitabine 
with paclitaxel for the first-line treatment of 
MBC in patients who have already received 
chemotherapy treatment with an anthracycline, 
compared with current standard of care. This 
reflects the licensed indication, and is an 
appropriate question for the NHS within the 
context of the available evidence.
Methods 
The ERG report comprised a critical review of the 
evidence for the clinical effectiveness and cost-
effectiveness of the technology based upon the 
manufacturer’s/sponsor’s submission to NICE as 
part of the STA process. It also included a critical 
assessment of the company’s submitted economic 
model. The ERG examined the excel model 
submitted by the manufacturer for accuracy and 
consistency and evaluated structural assumptions. 
In addition, the ERG estimated the survival 
probabilities and risk of disease progression 
for patients in the paclitaxel arm of the trial 
from survival plots reported in the conference 
presentation by Albain and colleagues,3 and fitted a 
parametric survival function to these data using the 
outputs from an ordinary least squares regression 
on a log-cumulative hazard.4 The ERG estimated 
the external validity of the manufacturer’s model 
by running it with survival estimates from the 
JHQG trial, and with median survival times for 
gemcitabine/paclitaxel and paclitaxel as shown 
in the JHQG trial (Figure 1). In addition, one-
way sensitivity analyses for key model parameters Health Technology Assessment 2009; Vol. 13: Suppl. 2
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were carried out (Table 1), and key input data were 
replaced with pooled estimates from plausible 
alternative sources (e.g. the estimates observed in 
the JHQG trial). A scenario analysis was conducted 
using effectiveness data from the JHQG trial 
for both gemcitabine/paclitaxel and paclitaxel, 
and the pooled estimates from trials including 
anthracycline-pretreated patients for other 
chemotherapy regimes. To determine whether the 
results of the company’s probabilistic sensitivity 
analysis are sensitive to the choice of included 
trials, the ERG reran the company’s probabilistic 
sensitivity analysis using the pooled estimates for 
overall survival, time to disease progression and 
overall response rate for paclitaxel monotherapy 
with values from the JHQG trial (Figure 2). The 
ERG constructed cost-effectiveness acceptability 
curves comparing each of four taxane-based 
chemotherapy regimes against each other (Figure 
3).
Results 
Summary of submitted 
clinical evidence
The clinical evidence for gemcitabine with 
paclitaxel compared with paclitaxel monotherapy 
as a treatment for MBC comes from the JHQG 
trial, which was published in conference abstracts5–7 
in 2003–4, but has not yet been fully published. 
The data in the industry submission come from 
the unpublished trial and so are mostly marked as 
commercial-in-confidence. Results from two other 
published trials are included in the submission to 
provide a comparison with docetaxel monotherapy8 
and docetaxel/capecitabine combined therapy.9 
The JHQG trial compared gemcitabine/paclitaxel 
(GT) with paclitaxel (T) in patients with MBC. 
The trial by Jones and colleagues8 compared 
docetaxel monotherapy with paclitaxel, and the 
trial by O’Shaughnessy and colleagues9 compared 
docetaxel monotherapy with docetaxel/capecitabine 
combination therapy.
Overall survival, the primary outcome measure 
for the JHQG trial, was approximately 3 months 
longer for the gemcitabine/paclitaxel arm (18.5 
months in Albain et al. abstract,5 18.6 months in 
manufacturer’s submission) than for the paclitaxel 
arm (15.8 months).7 This difference is of borderline 
statistical significance (p = 0.0489), but represents a 
clinically significant difference to patients. Results 
from the JHQG trial suggest that gemcitabine 
added to paclitaxel also improves tumour 
response and time to documented progression of 
disease compared with paclitaxel monotherapy. 
Haematological serious adverse events were more 
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FIGURE 1  Estimated survival for gemcitabine/paclitaxel and paclitaxel predicted by the model compared with Kaplan–Meier curves from 
the JHQG trial.Gemcitabine for the treatment of metastatic breast cancer
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common in the gemcitabine/paclitaxel arm than in 
the paclitaxel monotherapy arm.
In the absence of any formal methods of indirect 
comparison, there is insufficient robust evidence to 
compare the relative effectiveness of gemcitabine/
paclitaxel with docetaxel monotherapy or 
docetaxel/capecitabine combination therapy.
Summary of submitted cost-
effectiveness evidence
The cost-effectiveness analysis in the 
manufacturer’s submission uses a Markov state 
transition model to estimate the effect of treatment 
with five different chemotherapy regimes, adopting 
a 3-year time horizon. Base-case results are 
presented, with docetaxel monotherapy as the 
comparator for all interventions (assuming that 
docetaxel is the standard of care for UK practice). 
Additional scenario analyses are presented 
using alternative comparators and for a price 
reduction for paclitaxel once the patent expires. 
Treatment effects in the model are derived from 
pooling data from 15 clinical trials – only three 
of these are discussed in the clinical effectiveness 
section of the submission. No formal assessment 
of trial comparability or any quality assessment 
was presented. Health state utilities for different 
stages of disease progression and for patients 
experiencing treatment-related toxicity are 
used in the model to derive quality-adjusted 
life expectancy with each treatment. The base-
case cost-effectiveness estimate for gemcitabine/
paclitaxel relative to docetaxel is £17,168 per 
quality-adjusted life-year (QALY). When longer 
survival with docetaxel is assumed in a sensitivity 
analysis, the incremental cost-effectiveness ratio 
(ICER) increases to approximately £30,000 per 
QALY. Probabilistic sensitivity analysis estimates 
a 70% probability of gemcitabine/paclitaxel being 
cost-effective relative to docetaxel at an arbitrary 
threshold willingness to pay of £35,000.
The lack of formal quality assessment or 
assessment of the comparability of trials included 
in the input data, and the questionable validity of 
the indirect comparison method adopted, leads to 
considerable uncertainty over the cost-effectiveness 
of gemcitabine/paclitaxel. An illustrative analysis 
using a different method for indirect comparison 
presented in this report produces an ICER of 
£45,811 per QALY for gemcitabine/paclitaxel 
relative to docetaxel.
Commentary on the robustness 
of submitted evidence
Strengths
The structure of the manufacturer’s economic 
model is appropriate for the stated decision 
problem and reflects accepted methodology.
TABLE 1 Evidence review group one-way sensitivity analyses
Variable Base case
Inputs CE ratios (£)
Range (£) Lower Upper
Lower 
input
Upper 
input
Response rates (%) 46 39.0 52.9 17,199 17,052 147
Time to progression (weeks) 26 21.5 30.5 16,601 17,406 805
Overall survival (weeks) 80.60 CIC CIC 30,446 12,310 18,136
AE discontinuation rate (%) 6.7 3.7 9.7 16,335 17,994 1659
Health state utilities:
  Stable 0.80 0.65 0.92 23,656 13,546 10,110
  Response 0.72 0.60 0.83
  Progression 0.46 0.29 0.63
Adverse event, e.g. stable neuropathy, 
utility rates
0.70 0.55 0.83 17,396 16,972 424
Non-drug costs
Post–patient paclitaxel cost reduction 
(cost/course, £):
–25% +25% 17,988 16,348 1640
Gemcitabine/paclitaxel  2442 1862 2442 5872 17,168 11,296
Paclitaxel 1462   862 1462
AE, adverse events; CE, cost-effectiveness; CIC, commercial-in-confidence data removed.Health Technology Assessment 2009; Vol. 13: Suppl. 2
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Weaknesses
The manufacturer performed a systematic review, 
which identified two abstracts (and missed a 
third) reporting interim results of the JHQG trial. 
However, commercial-in-confidence data were 
presented as ‘confidential – not to be cited’ in the 
manufacturer’s submission; they are due to be 
published later this year.
Although a systematic review was carried out, 
there is contradiction and a lack of methodological 
rigour regarding a number of the references 
included for the economic evaluation. The ERG 
therefore considers that, although the model’s 
structure is appropriate, selection bias could 
potentially have affected the data inputs for the 
economic model.
The attempted indirect comparison in the clinical 
effectiveness section simply tabulates data from 
the JHQG trial and the two comparator trials. 
It might have been possible to perform a formal 
statistical indirect comparison of the JHQG trial 
with that by Jones and colleagues8 (docetaxel 
monotherapy versus paclitaxel) as they have a 
common comparator arm. However, differences in 
the patient characteristics between the trials may 
have invalidated such an approach.
FIGURE 2  Cost-effectiveness acceptability curves for gemcitabine/paclitaxel versus paclitaxel using (a) pooled estimates used in the base-
case analysis and (b) values from the JHQG trial. QALY, quality-adjusted life-year.Gemcitabine for the treatment of metastatic breast cancer
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Conclusions 
In the absence of a randomised controlled trial 
(RCT) directly comparing gemcitabine with 
docetaxel there does not appear to be sufficient 
evidence to compare the relative effectiveness of 
these treatments. The evidence for gemcitabine’s 
clinical effectiveness comes from an RCT 
comparing gemcitabine/paclitaxel with paclitaxel. 
However, the economic evaluation uses docetaxel 
as the comparator in the reference case.
The manufacturer suggests that gemcitabine 
should be considered as one option for first-line 
therapy for MBC in some patients, but does not 
appear to advocate that it should replace any of the 
current taxane treatments.
Summary of NICE guidance 
issued as a result of the STA 
The guidance issued by NICE in November 
2006 states that:
FIGURE 3  (a) Multiple cost-effectiveness acceptability curves (CEAC) comparing four taxane-based chemotherapy regimes. (b) CEA 
frontier. QALY, quality-adjusted life-year.Health Technology Assessment 2009; Vol. 13: Suppl. 2
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Gemcitabine in combination with paclitaxel, within 
its licensed indication, is recommended as an 
option for the treatment of metastatic breast cancer 
only when docetaxel monotherapy or docetaxel 
plus capecitabine is also considered appropriate.
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Abstract
This paper presents a summary of the submission’s 
evidence for the clinical effectiveness and cost-
effectiveness of varenicline for smoking cessation 
included four studies of varenicline (one of which 
was commercial-in-confidence) and a meta-analysis 
of varenicline versus nicotine replacement therapy 
(NRT), bupropion and placebo. Two controlled 
trials of 12 weeks of varenicline versus sustained-
release bupropion and placebo suggested that 
varenicline results in a statistically significant 
improvement in the odds of quitting at 12 weeks 
[odds ratio (OR) for quit rate during last 4 weeks 
of the study: 1.90–1.93 (p < 0.001) varenicline 
versus bupropion; 3.85 (p < 0.001) varenicline 
versus placebo). The ORs for sustained abstinence 
(weeks 9–52) for varenicline versus bupropion 
were 1.77 (p = 0.004) and 1.46 (p = 0.057), and 
for varenicline versus placebo were 2.66–3.09 
(p < 0.01). A placebo-controlled maintenance 
trial examined whether a further 12 weeks of 
varenicline would maintain the rate of abstinence 
among those successfully treated on one 12-week 
course [OR = 2.48 at week 24 for varenicline 
versus placebo (p < 0.001)]. The meta-analysis 
suggested that varenicline was superior to placebo 
and bupropion at 1 year and 3 months. Based on 
indirect comparisons, varenicline was reported 
to be superior to NRT when compared with 
placebo or all controls at 1 year and 3 months. 
The submission presented a state transition model 
to estimate the incremental cost-effectiveness of 
varenicline compared with bupropion, NRT and 
placebo. The model suggests that varenicline 
dominates bupropion, NRT and placebo.Treatment 
efficacy was based on a pooled analysis of 1-year 
quit rates from the varenicline clinical trials. 
Assuming a willingness-to-pay threshold range 
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of £20,000–30,000 per quality-adjusted life-year 
gained, the probabilistic sensitivity analysis suggests 
that the probability that varenicline produces the 
greatest amount of net benefit is 0.70. Weaknesses 
of the manufacturer’s submission include the 
assumption that only a single quit attempt using 
a single smoking cessation intervention is made, 
the presence of multiple computational errors 
and a limited sensitivity analysis. In conclusion, 
varenicline is likely to be clinically and cost-
effective for smoking cessation assuming that each 
user makes a single quit attempt. The key area of 
uncertainty concerns the long-term experience 
of subjects who have remained abstinent from 
smoking beyond 12 months. The guidance issued 
by the National Institute for Health and Clinical 
Excellence in July 2007 states that varenicline is 
recommended within its licensed indications as an 
option for smokers who have expressed a desire to 
quit smoking and that varenicline should normally 
be prescribed only as part of a programme of 
behavioral support.
Introduction 
The National Institute for Health and Clinical 
Excellence (NICE) is an independent organisation 
within the NHS that is responsible for providing 
national guidance on the treatment and care of 
people using the NHS in England and Wales. 
One of the responsibilities of NICE is to provide 
guidance to the NHS on the use of selected new 
and established health technologies, based on an 
appraisal of those technologies
NICE’s single technology appraisal (STA) 
process is specifically designed for the appraisal 
of a single product, device or other technology, 
with a single indication, for which most of the 
relevant evidence lies with one manufacturer 
or sponsor (Pfizer). Typically, it is used for new 
pharmaceutical products close to launch. The 
principal evidence for an STA is derived from a 
submission by the manufacturer/sponsor of the 
technology. In addition, a report reviewing the 
evidence submission is submitted by the evidence 
review group (ERG), an external organisation 
independent of NICE. This paper presents 
a summary of the ERG report for the STA of 
varenicline for smoking cessation.
Description of the 
underlying health problem
Three million deaths a year worldwide can be 
attributed to smoking,1 and it is a major etiological 
factor for lung cancer, cardiovascular disease and 
peripheral vascular disease. Smoking also causes 
respiratory disease, such as chronic obstructive 
pulmonary disease (COPD), including bronchitis 
and emphysema. Half of all smokers in the UK die 
prematurely of a smoking-related ailment, with 
the decrease in life expectancy for regular smokers 
under the age of 35 years who continue to smoke 
estimated to be about 8 years (www.nice.org.uk; 
accessed 15 December 2006).2 The annual cost to 
the NHS of treating patients with smoking-related 
disease is around £1.5 billion.3 
The proportion of adults in the UK who smoked 
cigarettes fell substantially during the 1970s and 
the early 1980s, after which it declined gradually 
until the early 1990s. Since this time it has 
plateaued, and in 2003–4 26% of adults aged 16 or 
over smoked cigarettes, an identical rate to that in 
2002/3. The gap between men and women smokers 
has narrowed, and in 2003–4 28% of men and 24% 
of women were cigarette smokers. In July 2004 the 
government set a new target to reduce the overall 
proportion of cigarette smokers in England to 21% 
or less by 2010 (www.statistics.gov.uk; accessed 15 
December 2006).
Inhaled nicotine is strongly addictive and stopping 
smoking results in craving and withdrawal 
symptoms. However, smokers who quit before the 
age of about 35 years have a life expectancy only 
slightly less than those who have never smoked. 
Even cessation in middle age improves health and 
substantially reduces the excess risk of death, and 
quitting at any age provides both immediate and 
long-term health benefits. It is estimated that about 
4 million smokers a year attempt to quit, but that 
only 3–6% of these (1–2% of all smokers) succeed 
(www.nice.org.uk; accessed 15 December 2006). 
Smokers have a range of options when the decision 
has been made to attempt to quit, the most 
common of which is unaided cessation, so-called 
‘cold turkey’. Other alternatives are bupropion, 
counselling with or without pharmacotherapy, 
hypnosis, acupuncture or use of over-the-counter 
nicotine replacement therapy (NRT).
GPs in the UK maintain a record of the smoking 
habits of all patients and are encouraged to offer 
advice and support to smokers to help them 
quit. Smokers can be referred to a local smoking 
cessation service where counselling will be offered 
and, if deemed appropriate, pharmacological 
support prescribed.Health Technology Assessment 2009; Vol. 13: Suppl. 2
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Scope of the ERG report
The principal research question is whether 
varenicline is clinically effective and cost-
effective compared with NRT or bupropion, an 
antidepressant, in supporting smoking cessation 
in adults who smoke tobacco products and have 
indicated a desire to quit smoking. Varenicline 
is a selective nicotinic receptor partial agonist 
that is indicated for smoking cessation in adults. 
The recommended dose is 1 mg of varenicline 
twice daily following a 1-week titration period. At 
the time of writing of the ERG report the cost of 
varenicline was £1.95 per day per patient.
Key outcomes presented within the sponsor 
submission include: survival, morbidity related to 
smoking, quit rates, adverse effects of treatment, 
health-related quality of life and cost-effectiveness. 
Clinical effectiveness outcomes are presented only 
for the intention to treat populations within the 
clinical trials; subgroup analyses are not presented.4
Methods 
The ERG report3 comprised a critical review of 
the evidence for the clinical effectiveness and cost-
effectiveness of the technology based upon the 
manufacturer’s/sponsor’s submission to NICE as 
part of the STA process. 
The sponsor commissioned an independent review 
group to undertake a meta-analysis and indirect 
comparison of controlled trials. Aside from the 
indirect comparison, the McMaster review makes 
comparisons of clinical effectiveness previously 
undertaken in three (publicly funded) Cochrane 
reviews, the latest versions of which are by Silagy et 
al.5 (NRT), Hughes et al.6 (bupropion) and Cahill et 
al.7 (varenicline). As these reviews were all relatively 
recent we did not undertake new searches. We used 
the Cochrane Tobacco Addiction Group to identify 
studies that were inappropriately excluded from 
the review. The ERG reran the meta-analyses and 
undertook an additional indirect comparison to 
validate the manufacturer’s estimates of treatment 
effect.
A mathematical model to estimate the incremental 
cost-effectiveness of varenicline versus bupropion, 
NRT and placebo was presented by the sponsor; 
this model was made available to the ERG for 
scrutiny. The model was based upon an earlier 
smoking cessation model [the Health and 
Economic Consequences of Smoking (HECOS) 
model] previously reported by Orme et al.8 The 
model uses the state transition methodology to 
simulate the experiences of individuals following 
an initial attempt to quit smoking. The model 
includes five morbidities that are related to 
smoking: COPD, lung cancer, coronary heart 
disease (CHD) events, asthma and stroke. These 
morbidities were included in the model as they 
were reported by the sponsor to account for the 
greatest mortality, morbidity and cost associated 
with smoking. The ERG critically appraised 
the sponsor’s model and undertook a detailed 
assessment of its internal and external consistency. 
Results 
Summary of submitted 
clinical evidence
The sponsor submission reported the methods 
and results of four clinical studies of varenicline. 
The first two studies were double-blind controlled 
trials of 12 weeks of varenicline versus sustained-
release bupropion and placebo. These studies 
suggested that varenicline results in a statistically 
significant improvement in the odds of quitting 
at 12 weeks. The odds ratio (OR) for the quit rate 
during the last 4 weeks of the study was 1.90–1.93 
(p < 0.001) for varenicline versus bupropion, and 
3.85 (p < 0.001) for varenicline versus placebo. In 
terms of sustained abstinence (weeks 9–52), the OR 
for varenicline versus bupropion was significantly 
different in one study (OR = 1.77, p = 0.004), 
but not in another (OR = 1.46, p = 0.057). When 
compared against placebo, the OR for the 
sustained quit rate for varenicline versus placebo 
was 2.66–3.09; this improvement was statistically 
significant in both studies (p < 0.01). The third 
study was a placebo-controlled maintenance trial 
that examined whether a further 12 weeks of 
varenicline treatment would maintain the rate of 
abstinence among those successfully treated on one 
12-week course of varenicline. At week 24, patients 
who received varenicline had an OR of 2.48 of 
maintaining abstinence compared with patients 
who received placebo; this improvement was 
statistically significant (p < 0.001). For weeks 13–52, 
the improvement remained significant (OR = 1.34, 
p < 0.02). The fourth study was an open-label study 
that compared 12 weeks of varenicline therapy with 
10 weeks of NRT transdermal patch. The results of 
this study were held as commercial-in-confidence.
The sponsor submission also detailed a large meta-
analysis of varenicline versus NRT, bupropion and 
placebo. This analysis suggested that varenicline 
was superior to placebo and bupropion at 1 year 
and also at approximately 3 months. Based on Varenicline in the management of smoking cessation: a single technology appraisal
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indirect comparisons, varenicline was reported to 
be superior to NRT when compared with placebo 
controls or to all controls at 1 year and at 3 months.
Summary of submitted cost-
effectiveness evidence
The submission reports the methods and results of 
a state transition model (the Benefits of Smoking 
Cessation on Outcomes or BENESCO model) 
to estimate the incremental cost-effectiveness of 
varenicline compared with bupropion, NRT and 
placebo. The model suggests that varenicline 
dominates (i.e. is more effective and less expensive 
than) bupropion, NRT and placebo. Treatment 
efficacy for each of the interventions is based on 
the results of a pooled analysis of 1-year quit rates 
sourced from the clinical trials of varenicline. 
Beyond this point the model assumes that short-
term efficacy translates into long-term health gains 
and associated cost savings. This assumption of 
sustained benefit is subject to a substantial degree 
of uncertainty. Shorter time horizons may be less 
uncertain, but may underestimate the benefits 
of varenicline. Longer time horizons provide 
more favourable cost-effectiveness estimates for 
varenicline yet are subject to a much greater 
degree of uncertainty. Assuming a willingness-
to-pay threshold range of £20,000–30,000 per 
quality-adjusted life-year gained, the probabilistic 
sensitivity analysis suggests that the probability that 
varenicline produces the greatest amount of net 
benefit is estimated to be 0.70. 
Commentary on 
the robustness of 
submitted evidence
Strengths
The manufacturers have recruited a team of 
researchers from McMaster University (Hamilton, 
Ontario) to produce and publish a systematic 
review, which they have used as the basis for their 
analysis. 
The structural assumptions included in the 
submission model appear to be intuitively sensible, 
and the costs and consequences of most important 
smoking-related morbidities (lung cancer, COPD, 
asthma, CHD and stroke) are included in the 
analysis.
Weaknesses
The manufacturer’s use of indirect comparisons 
is inappropriate because they had access to a 
direct comparison (the commercial-in-confidence 
randomised control trial). The indirect comparison 
was also flawed because it was based on a meta-
analysis that inappropriately included and 
excluded studies, the effect of which would have 
been to exaggerate the effect size of varenicline. 
The model assumes only a single quit attempt 
using a single smoking cessation intervention 
(varenicline, bupropion, NRT or placebo). In 
reality, smokers may attempt to quit more than 
once using several smoking cessation technologies. 
The costs and health outcomes of repeated quit 
attempts are not considered within the evaluation.
The model extrapolates lifetime outcomes for 
subjects attempting to quit smoking (up to 81 years 
of extrapolated costs and consequences) based on 
a pooled analysis of 1-year efficacy outcomes from 
clinical trials. 
The model uses a large number of parameter 
values derived from US studies that may not 
reflect the smoking/abstinence behaviour of the 
population of England and Wales.
Methods for identifying and selecting costs and 
health utilities associated with morbidities are not 
reported or justified within the sponsor submission. 
The presence of multiple computational errors 
should be borne in mind when considering cost-
effectiveness results reported within the sponsor 
submission. Most notable was a structural error that 
violated a key condition of the Markov approach; 
consequently, the probability of being in any health 
state at any point in time does not consistently sum 
to 1 over the duration of the model time horizon. 
The sensitivity analysis presented within the 
submission is very narrow and underestimates 
the true uncertainty surrounding the incremental 
cost-effectiveness of varenicline. In particular, the 
probabilistic sensitivity analysis was restricted to a 
limited number of parameters and is inherently 
flawed. The true uncertainty surrounding the 
incremental cost-effectiveness of varenicline has 
not been appropriately addressed within the 
submission.Health Technology Assessment 2009; Vol. 13: Suppl. 2
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The external validity of the model has not been 
demonstrated by the sponsor. 
Conclusions 
Varenicline is likely to be clinically effective and 
cost-effective if one assumes, as the clinical trials 
and the manufacturer’s model do, that each user 
makes a single quit attempt. The key area of 
uncertainty concerns the long-term experience 
of subjects who have remained abstinent from 
smoking beyond 12 months. The health economic 
model makes an assumption of sustained benefit 
for the remaining 81 years of the time horizon. 
The validity of the assumption of sustained benefit 
between treatment groups is unclear.
Summary of NICE guidance 
issued as a result of the STA 
At the time of writing the guidance document 
issued by NICE in July 20079 states that: 
1.  Varenicline is recommended within its licensed 
indications as an option for smokers who have 
expressed a desire to quit smoking.
2.  Varenicline should normally be prescribed only 
as part of a programme of behavioral support.
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Abstract
This paper presents a summary of the evidence 
review group report into the clinical effectiveness 
and cost-effectiveness of alteplase for the treatment 
of acute ischaemic stroke, in accordance with the 
licensed indication, based upon the evidence 
submission from the manufacturer to the National 
Institute for Health and Clinical Excellence (NICE) 
as part of the single technology appraisal (STA) 
process. The submitted clinical evidence included 
several randomised controlled trials indicating 
that, in highly selected patients, alteplase 
administered at a licensed dose within 3 hours of 
the onset of acute ischaemic stroke is associated 
with a statistically significant reduction in the risk 
of death or dependency at 3 months compared 
with placebo, despite a significantly increased 
risk of symptomatic intracranial haemorrhage 
within the first 7–10 days. Data from the National 
Institute of Neurological Disorders and Stroke 
(NINDS) trial suggest that the benefit of treatment 
is sustained at 6 and 12 months. However, data 
from observational studies suggest that few patients 
with acute ischaemic stroke will be eligible for 
alteplase therapy under the terms of the current 
licensing agreement. In particular, many patients 
will be excluded by virtue of their age, and many 
more by the restriction of therapy to patients in 
whom treatment can be initiated within 3 hours of 
symptom onset. The manufacturer’s submission 
included a state transition model evaluating the 
impact of treatment with alteplase within 3 hours 
of onset of stroke symptoms compared to standard 
treatment reporting that, in the base-case analysis, 
alteplase was both less costly and more effective 
than standard treatment. This increased to a 
maximum of approximately £4000 upon one-
way sensitivity analysis of the parameters. The 
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probabilistic sensitivity analysis presented within 
the submission suggests that the probability that 
alteplase has a cost-effectiveness ratio greater than 
£20,000 per quality-adjusted life-year (QALY) 
gained is close to 1 (0.99). The results of the 
short-term model demonstrate that alteplase is 
cost-effective over a 12-month period, with an 
incremental cost-effectiveness ratio of £14,026 
per QALY gained. This increased to a maximum 
of £50,000 upon one-way sensitivity analysis of 
the parameters. At 12 months, the probabilistic 
sensitivity analysis presented within the submission 
suggests that the probability that alteplase has a 
cost-effectiveness ratio greater than £20,000 per 
QALY gained is approximately 0.7. The guidance 
issued by NICE in April 2007 as a result of the 
STA states that alteplase is recommended for the 
treatment of acute ischaemic stroke only when 
used by physicians trained and experienced in the 
management of acute stroke and in centres with the 
required facilities.
Introduction
The National Institute for Health and Clinical 
Excellence (NICE) is an independent organisation 
within the NHS that is responsible for providing 
national guidance on the treatment and care of 
people using the NHS in England and Wales. 
One of the responsibilities of NICE is to provide 
guidance to the NHS on the use of selected new 
and established health technologies, based on an 
appraisal of those technologies.
NICE’s single technology appraisal (STA) process 
is specifically designed for the appraisal of a single 
product, device or other technology, with a single 
indication, for which most of the relevant evidence 
lies with one manufacturer or sponsor.1 Typically, 
it is used for new pharmaceutical products close 
to launch. The principal evidence for an STA is 
derived from a submission by the manufacturer/
sponsor of the technology. In addition, a report 
reviewing the evidence submission is submitted 
by the evidence review group (ERG); an external 
organisation independent of NICE. This paper 
presents a summary of the ERG report for the STA 
of alteplase for the treatment of acute ischaemic 
stroke.2
Description of the underlying 
health problem
‘Stroke’ is a term used to refer to the clinical 
syndrome that results from the interruption 
of the blood supply to an area of the brain. 
Approximately 85% of all strokes occur when the 
blood supply to the brain is blocked, either by a 
blood clot or by narrowing of the blood vessels: 
such strokes are termed ischaemic strokes.3 Most 
other strokes occur when a blood vessel in or 
around the brain ruptures: these are termed 
haemorrhagic strokes.3
In England, stroke is one of the top three causes 
of death.3 It is also the leading cause of adult 
disability;4 at least 300,000 people in England live 
with moderate to severe disabilities as a result of 
stroke.3
Alteplase is an enzyme that causes blood clots 
to dissolve. It is therefore of potential value 
in ischaemic stroke because it may enable the 
restoration of the blood supply to the affected 
area of the brain. However, it is also associated 
with a risk of intracerebral haemorrhage. 
Moreover, because it dissolves blood clots, its 
use in haemorrhagic stroke is potentially fatal 
or disabling. Alteplase is not licensed for use in 
patients older than 80 years.
Scope of the evidence 
review group report
The principal research question relates to the 
clinical effectiveness and cost-effectiveness of 
alteplase for the treatment of acute ischaemic 
stroke. The manufacturer’s scope restricts the 
intervention to intravenous alteplase given to 
adults with ischaemic stroke within 3 hours of 
symptom onset, in a secondary care setting, under 
the guidance of experienced stroke and neuro-
imaging specialists, and after prior exclusion of 
intracranial haemorrhage. The scope restricts the 
comparator to placebo or standard medical and 
supportive management without thrombolysis. 
This is because no thrombolytic treatment other 
than alteplase is licensed in the UK for use in acute 
ischaemic stroke, and other stroke treatment or 
prevention therapies that function in different ways 
would not be relevant comparators.
The single most clinically relevant and important 
outcome measure is the proportion of patients 
suffering death or dependency (reported as a score 
of 3–6 inclusive on the modified Rankin scale). 
This captures in one measure alteplase’s impact 
on both the proportion of patients making a good 
functional recovery and the proportion suffering 
asymptomatic intracranial haemorrhage (SICH), 
an outcome associated with death or increased 
disability. Other relevant outcomes include survival; 
neurological deficit; mental health (including 
anxiety and depression); adverse effects of Health Technology Assessment 2009; Vol. 13: Suppl. 2
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treatment (including bleeding events); and health-
related quality of life. Economic outcomes include 
cost per quality-adjusted life-year (QALY) gained.
Methods
The ERG report comprised a critical review of 
the evidence for the clinical evidence and cost-
effectiveness of the technology based upon the 
manufacturer’s submission to NICE as part of the 
STA process. In addition, in an attempt to ensure 
that no relevant randomised controlled trials were 
overlooked, the ERG reran in MEDLINE both 
the manufacturer’s search strategy and the search 
strategy previously used in the Cochrane review 
of thrombolysis for acute stroke.5 This established 
that, while the manufacturer’s MEDLINE search 
strategy identified the key publication relating to 
each of the included trials, it did not identify the 
important reanalysis of the National Institute of 
Neurological Disorders and Stroke (NINDS) study,6 
two supplementary analyses that the submission 
identified as relevant,7,8 or the Cochrane review5 on 
which the submission drew heavily.
The manufacturer’s submission also drew on 
evidence from a number of observational studies. 
It is not clear how these were identified. The 
submission implied that the same search strategies 
were used to identify both randomised controlled 
trials and studies investigating or evaluating service 
delivery or provision of technology. However, 
as the manufacturer’s EMBASE and MEDLINE 
search strategies both contained a term limiting the 
search to clinical trials, neither would have reliably 
identified observational studies. Supplementary 
data provided by the manufacturer stated that a 
systematic search was undertaken for observational 
studies, but did not provide a relevant search 
strategy and, within the time available, the ERG 
was not able to conduct supplementary searches 
to ensure that relevant observational studies were 
not missed. The manufacturer’s exclusion criteria 
arbitrarily excluded observational studies that were 
small (< 100 patients) or added nothing to the 
conclusions that could be drawn from the larger 
studies. No indication was given as to the number 
of studies that were excluded for these reasons. 
Inclusion of those studies that were excluded 
because they did not contain a new message would 
have enabled estimation of the strength of evidence 
for the messages contained in the included studies.
The manufacturer did not undertake independent 
meta-analyses, but referred to those undertaken for 
the Cochrane review (which were calculated as odds 
ratios using the Peto fixed-effects method),5 and 
the pooled analysis of the Alteplase Thrombolysis 
for Acute Noninterventional Therapy in 
Ischemic Stroke (ATLANTIS) A and B, European 
Cooperative Acute Stroke Study (ECASS) II, and 
NINDS 1 and 2 trials8 (which again used the 
odds ratio). The ERG therefore carried out meta-
analyses to explore the effects of excluding a study 
(ECASS I) that used an unlicensed dose of alteplase 
and of presenting the results as relative risks, as 
required by NICE, rather than as Peto odds ratios.
The ERG had concerns about some of the methods 
used by the manufacturer in the cost-effectiveness 
modelling. This included the use of odds ratios in 
the model instead of relative risks, and the length 
of the model cycle time. The manufacturers were 
asked to justify the use of these methods and 
were requested to perform additional analyses 
using methods considered by the ERG to be 
more appropriate. In all cases the manufacturers 
complied with these requests. The additional 
analyses showed no meaningful differences in 
either the direction or the magnitude of the results 
compared with the original work.
Results
Summary of submitted 
clinical evidence
Evidence from randomised controlled trials 
indicates that, in highly selected patients, alteplase 
administered at a licensed dose within 3 hours of 
the onset of acute ischaemic stroke is associated 
with a statistically significant reduction in the risk 
of death or dependency at 3 months compared 
with placebo [relative risk (RR) 0.82, 95% 
confidence interval (CI) 0.72 to 0.93, absolute risk 
reduction 11%; Figure 1], despite a significantly 
increased risk of SICH within the first 7–10 days 
[RR 4.24, 95% confidence interval (CI) 1.52 to 
11.83, absolute risk increase 6%]. Data from the 
NINDS trial, the only study which presented data 
relating to a time point later than 3 months from 
stroke onset, suggest that the benefit of treatment is 
sustained at 6 and 12 months.
However, data from observational studies suggest 
that few patients with acute ischaemic stroke will 
be eligible for alteplase therapy under the terms 
of the current licensing agreement. In particular, 
many patients will be excluded by virtue of their 
age, and many more by the restriction of therapy to 
patients in whom treatment can be initiated within 
3 hours of symptom onset. In principle, it may be 
possible to increase the proportion of patients who Alteplase for the treatment of acute ischaemic stroke: a single technology appraisal
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both reach hospital and are assessed for alteplase 
therapy within 3 hours, but to do so would require 
substantial investment in public education, and 
possibly also service reconfiguration. Moreover, 
the risk of major protocol violations in the 
administration of alteplase should be noted. In 
two comprehensive independent community-
based studies, the Cleveland9 and Connecticut10 
studies (of which only the former was cited in 
the manufacturer’s submission), such violations, 
most of which appeared to have been accidental,10 
affected 67% of patients receiving alteplase in 
Connecticut and 50% in the Cleveland area.
Summary of submitted cost-
effectiveness evidence
A state transition model was used to evaluate 
the impact of treatment with alteplase within 3 
hours of onset of stroke symptoms compared to 
standard treatment. The time horizon for this 
long-term model was 40 years. In addition, a short-
term (12-month follow-up) model is included. 
The model is based on work published as part 
of the Health Technology Appraisal (HTA) of 
thrombolytic therapy by Sandercock et al.11
The main data source for the model is a Cochrane 
review meta-analysis of the NINDS,12 ECASS I,13 
ECASS II,14 ATLANTIS A,15 ATLANTIS B16 and 
Haley et al.17 studies. Outcomes from this meta-
analysis are extrapolated over a time horizon of 40 
years in order to assess the long-term benefits and 
costs of alteplase. The model takes into account the 
increased rate of haemorrhage seen in alteplase-
treated patients.
The health states used within the model and the 
costs and utilities associated with each health state 
are considered to be appropriate for the required 
analysis.
The Boehringer Ingelheim model estimated that, 
in the base-case analysis, alteplase was both less 
costly and more effective than standard treatment. 
This increased to a maximum of approximately 
£4000 upon one-way sensitivity analysis of the 
parameters.
The probabilistic sensitivity analysis presented 
within the submission suggests that the probability 
that alteplase has a cost-effectiveness ratio greater 
than £20,000 per QALY gained is close to 1 (0.99).
The results of the short-term model demonstrate 
that alteplase is cost-effective over a 12-month 
period, with an incremental cost-effectiveness 
ratio (ICER) of £14,026 per QALY gained. This 
increased to a maximum of £50,000 upon one-way 
sensitivity analysis of the parameters.
At 12 months, the probabilistic sensitivity analysis 
presented within the submission suggests that the 
probability that alteplase has a cost-effectiveness 
ratio greater than £20,000 per QALY gained is 
approximately 0.7.
Commentary on the robustness 
of submitted evidence
The evidence for the clinical effectiveness of 
alteplase when used within the 3-hour licensed 
window for the treatment of acute ischaemic 
FIGURE 1  All patients treated within 3 hours: death or dependency at 3 months. ATLANTIS, Alteplase Thrombolysis for Acute 
Noninterventional Therapy in Ischemic Stroke; CI, confidence interval; ECASS, European Cooperative Acute Stroke Study; NINDS, National 
Institute of Neurological Disorders and Stroke; RR, relative risk.
Review:  Alteplase
Comparison:  10 Time to treatment <3 hours
Outcome:  03 Death or dependency at 3 months
Study or 
sub-category
Alteplase
n/N
Control
n/N
RR (random) 
95% CI
Weight
%
RR (random) 
95% CI
ATLANTIS A 0–3 hours 7/10 7/12 3.95 1.20 (0.64–2.25)
ATLANTIS B 0–3 hours 3/13 12/26 1.34 0.50 (0.17–1.47)
ECASS II 0–3 hours 39/81 44/77 17.58 0.84 (0.63–1.13)
NINDS 155/312 192/312 77.13 0.81 (0.70–0.93)
Total (95% CI) 416 427 100.00 0.82 (0.72–0.93)
Total events: 204 (Alteplase), 255 (Control)
Test for heterogeneity: χ
2 2  = 2.33, df = 3 (p  = 2.33, df = 3 (  = 2.33, df = 3 (  = 0.51), I  = 0%
Test for overall effect: z = 3.10 (p  = 3.10 (  = 3.10 (  = 0.002)
0.001 0.1 0.01 1 10 100 1000
 Favours control  Favours treatmentHealth Technology Assessment 2009; Vol. 13: Suppl. 2
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stroke is not robust and, as noted in a recent 
Cochrane review,5 should be treated with extreme 
caution. It is based on a total of only 416 
patients who received the current licensed dose 
of alteplase within the 3-hour time window (see 
Figure 1). Moreover, 312 of these patients were 
enrolled in one trial, the NINDS trial, in which a 
substantial imbalance in baseline stroke severity, 
a key prognostic factor, favoured alteplase.11 An 
additional analysis undertaken by the Cochrane 
reviewers suggested that the imbalance probably 
caused the effect of alteplase on death and 
dependency to be overestimated by around 3%.5 
However, a subsequent independent analysis of 
the NINDS data considered that there was no 
evidence that the imbalance in the distribution 
of baseline NIHSS (National Institute for Health 
Stroke Scale) scores had either a statistically or 
a clinically significant effect on the trial results.6 
The randomised trials were not stratified by any 
potential prognostic factor other than time to 
treatment, and therefore any post hoc analyses 
designed to explore the extent to which different 
groups might benefit from therapy can only be 
regarded as hypothesis generating. Nonetheless, 
it is interesting to note that a pooled analysis of 
data from the ATLANTIS A and B, ECASS II, and 
NINDS trials18 appeared to indicate that alteplase 
therapy was of significant benefit in women, but 
not in men (Table 1).
The model structure is appropriate and allows 
sensitivity analysis to be carried out easily. Given a 
40-year time horizon, one-way sensitivity analysis 
suggests that variations in the majority of the 
parameters do not have a large effect upon the 
ICER. Alteplase dominates (i.e. costs less and is 
more effective than) standard treatment; potential 
parameter variations are unlikely to increase the 
ICER beyond the currently accepted threshold 
values.19
The results at 12 months, when the full lifetime 
costs associated with disability due to stroke 
and the QALY gain associated with increased 
survival are not captured, indicate that alteplase 
is still cost-effective. No weaknesses in the model 
structure were identified that would alter the 
results significantly. However, the model rests on 
evidence for the clinical effectiveness of alteplase 
administered with 3 hours of symptom onset which, 
as noted above, is not robust. Moreover, although 
the risks and benefits of alteplase are unknown 
beyond 12 months, the manufacturer’s health 
economic model has used a lifetime horizon of 40 
years. In addition, the economic evaluation relies 
heavily on the results of the NINDS trial in which, 
as noted above, a substantial imbalance in baseline 
stroke severity favoured alteplase. Thus, the results 
of the cost-effectiveness analysis should be treated 
with extreme caution.
One important issue which is not explicitly taken 
into account in the economic modelling is the 
possible impact of trying to increase the number 
of patients who could be treated within the 3-hour 
window. This could have a significant cost impact to 
the NHS in terms of both the need to educate the 
public on the importance of early treatment and 
potential substantial service reconfiguration.
Conclusions
The evidence from randomised controlled trials 
suggests that, in highly selected patients, alteplase 
administered within 3 hours of the onset of acute 
ischaemic stroke is associated with a statistically 
significant reduction in the risk of death or 
dependency at 3 months compared with placebo, 
despite the statistically significant increase in the 
risk of early SICH. However, this evidence should 
be treated with extreme caution as it is based 
on a total of only 416 patients who received the 
current licensed dose of alteplase, and 312 of 
these patients were included in a trial in which a 
substantial imbalance in baseline stroke severity, a 
key prognostic factor, favoured alteplase.
TABLE 1  Proportion of patients with a favourable outcome at 90 days [modified Rankin Scale (mRS) 0–1]: pooled analysis of data from 
the ATLANTIS A and B, ECASS II, and NINDS studies18 
Alteplase Placebo
p-value 
(alteplase vs placebo)
Men 38.5% 36.7% 0.52
Women 40.5% 30.3% < 0.001
p-value (men vs women) 0.50 0.03
Kent et al.18 did not present these data in such as way as to allow the calculation of relative risks and confidence intervals.Alteplase for the treatment of acute ischaemic stroke: a single technology appraisal
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Observational studies suggest that few patients 
with ischaemic stroke will be eligible for alteplase 
therapy under the terms of the current licensing 
agreement. In particular, many patients will be 
excluded because they are older than 80 years, and 
many more will be excluded because treatment 
cannot be initiated within 3 hours of symptom 
onset. Any increase in the number of patients in 
whom treatment can be initiated within 3 hours 
is likely to require substantial efforts in terms of 
public education and service reconfiguration.
The critical appraisal of the Boehringer Ingelheim 
model undertaken by the ERG suggests that 
alteplase can result in long-term cost savings and is 
more effective than standard treatment.
In the short-term, when the full lifetime costs 
associated with disability due to stroke and the 
QALY gain associated with increased survival are 
not captured, alteplase was still shown to be cost-
effective compared to standard treatment.
Summary of NICE guidance 
issued as a result of the STA
At the time of writing, the final appraisal 
determination document issued by NICE in April 
2007 states that:
Alteplase is recommended for the treatment of 
acute ischaemic stroke when used by physicians 
trained and experienced in the management of 
acute stroke. It should only be administered in 
centres with facilities that enable it to be used in 
full accordance with its marketing authorisation.
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Abstract
This paper presents a summary of the evidence 
review group’s critical review of the evidence for 
the clinical effectiveness and cost-effectiveness of 
rituximab for the treatment of severe rheumatoid 
arthritis (RA) following failure of previous therapy, 
including one or more tumour necrosis factor-α 
inhibitors (TNFi), compared with current standards 
of care, based upon the manufacturer’s submission 
to the National Institute for Health and Clinical 
Excellence (NICE) as part of the single technology 
appraisal (STA) process. The submission’s clinical 
evidence came from one randomised, placebo-
controlled, double-blind trial (REFLEX – Random 
Evaluation of Long-term Efficacy of Rituximab in 
Rheumatoid Arthritis) comparing rituximab plus 
methotrexate (MTX) with placebo plus MTX in 
517 patients with long-standing refractory RA. 
Rituximab plus MTX was more effective than 
placebo plus MTX across a range of primary 
and secondary outcome measures, e.g. American 
College of Rheumatology (ACR) responses, Health 
Assessment Questionnaire (HAQ). However, this 
evidence cannot be used directly to address the 
manufacturer’s analysis of the decision problem 
because, in the REFLEX trial, rituximab was 
not compared with a relevant comparator (e.g. 
leflunomide or second or third TNFi). Long-
term efficacy data for retreatment with rituximab 
are favourable, with an estimated mean time to 
retreatment of 307 days (n = 164). Evidence from 
a further five trials is presented as the basis for 
indirect comparisons with other disease-modifying 
antirheumatic drugs (DMARDs); however, it 
is not clear that all relevant clinical studies 
HTA 06/53/01
Date of ERG submission: 
February 2006
TAR Centre(s): 
Liverpool Reviews and Implementation Group
List of authors: 
A Bagust, A Boland, J Hockenhull, N Fleeman, J 
Greenhalgh, Y Dundar, C Proudlove, T Kennedy, R 
Moots, P Williamson and R Dickson
Contact details:
Rumona Dickson (LRiG Director), Liverpool Reviews 
and Implementation Group, Sherrington Buildings, 
University of Liverpool, Ashton Street, Liverpool L69 
3GE, UK 
E-mail: LRiG@liv.ac.uk
The research reported in this article of the journal 
supplement was commissioned and funded by the 
HTA programme on behalf of NICE as project number 
06/53/01. The assessment report began editorial review 
in September 2008 and was accepted for publication 
in March 2009. See the HTA programme web site 
for further project information (www.hta.ac.uk). This 
summary of the ERG report was compiled after the 
Appraisal Committee’s review.
The views and opinions expressed therein are those of 
the authors and do not necessarily reflect those of the 
Department of Health.
Discussion of ERG reports is invited. Visit the HTA website 
correspondence forum (http://www.hta.ac.uk/correspond).
DOI: 10.3310/hta13suppl2/04Rituximab for the treatment of rheumatoid arthritis
24
have been included in the indirect comparison 
exercise, the rationale for the choice of indirect 
comparison method adopted is unclear and the 
indirect comparison method used to adjust the 
ACR responses only uses a single value for the 
reference placebo. The submitted microsimulation 
Markov model was based upon the REFLEX 
trial. For the ‘NICE-recommended’ scenario 
and the ‘sequential TNFi’ scenario, the original 
submission reports incremental cost-effectiveness 
ratios (ICERs) of £14,690 and £11,601 per quality-
adjusted life-year (QALY) gained respectively. 
After model assumptions were adjusted to more 
realistic estimates by the ERG, the ICERs for the 
NICE-recommended scenario and the sequential 
use of TNFi range from £37,002 to £80,198 per 
QALY gained and from £28,553 to £65,558 per 
QALY gained respectively. The guidance issued 
by NICE in August 2007 states that rituximab in 
combination with methotrexate is recommended 
as an option for the treatment of adults with 
severe active rheumatoid arthritis who have had 
an inadequate response to or intolerance of other 
DMARDs including treatment with at least one 
TNFi therapy. 
Introduction
The National Institute for Health and Clinical 
Excellence (NICE) is an independent organisation 
within the NHS that is responsible for providing 
national guidance on the treatment and care of 
people using the NHS in England and Wales. 
One of responsibilities of NICE is to provide 
guidance to the NHS on the use of selected new 
and established health technologies, based on an 
appraisal of those technologies.
NICE’s single technology appraisal (STA) process 
is specifically designed for the appraisal of a single 
product, device or other technology, with a single 
indication, for which most of the relevant evidence 
lies with one manufacturer or sponsor.1 Typically, 
it is used for new pharmaceutical products close 
to launch. The principal evidence for an STA is 
derived from a submission by the manufacturer/
sponsor of the technology. In addition, a report 
reviewing the evidence submission is submitted 
by the evidence review group (ERG), an external 
organisation independent of NICE. This paper 
presents a summary of the ERG report for the 
STA of rituximab for the treatment of rheumatoid 
arthritis.2
Description of the 
underlying health problem
Rheumatoid arthritis (RA) is a chronic systemic 
autoimmune disorder, which is primarily 
characterised by inflammation and swelling of 
multiple synovial joints. The primary symptoms of 
pain, fatigue and disability are chronic and related 
to the underlying inflammatory disease process. 
Furthermore, patients with RA have a reduced 
life expectancy.3–7 There is no cure for RA and so 
the therapeutic goals are a remission of symptoms 
involving the joints, a return of full function and 
the maintenance of remission.
RA affects between 0.5% and 1% of the population, 
equating to approximately 400,000 people in 
England and Wales, with the prevalence being 
three times higher in women than in men.8–11 
Diagnosis is generally between the ages of 40 and 
80 years8–11 and within 5 years one-third of patients 
are unable to work,12 increasing the substantial 
economic burden of RA.
Scope of the ERG report
The ERG report presents the results of the 
assessment of the manufacturer’s (Roche Products) 
evidence submission regarding the use of rituximab 
for the treatment of severe RA following failure of 
previous therapy, including one or more tumour 
necrosis factor-α inhibitor (TNFi), compared with 
current standards of care. The report includes 
an assessment of both the clinical effectiveness 
and cost-effectiveness evidence submitted by the 
manufacturer. 
Rituximab (known as MabThera® in the UK and 
Rituxan® in the USA) is a monoclonal antibody 
that depletes the CD20+ B cells implicated in 
the immunopathogenesis of RA. In July 2006 
rituximab plus methotrexate (MTX) was licensed 
in Europe for the treatment of severe RA following 
the failure of conventional treatments, including 
at least one TNFi. The licensing submission 
was supported by a phase III study13 comparing 
rituximab plus MTX with placebo plus MTX 
along with evidence from phase II trials.14–15 
It is restricted to use by specialist physicians 
experienced in the diagnosis and treatment of RA.Health Technology Assessment 2009; Vol. 13: Suppl. 2
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Methods 
The ERG report comprised a critical review 
of the evidence of the clinical effectiveness 
and cost-effectiveness of the technology based 
upon the manufacturer’s/sponsor’s submission 
to NICE as part of the STA process. The ERG 
assessed the quality of the manufacturer’s clinical 
effectiveness review using a standard checklist. 
The ERG conducted a detailed evaluation of the 
manufacturer’s economic model. Cost–utility 
estimates were recalculated taking changes in 
parameters and assumptions into account. For 
example, mortality rates, the evidence base 
for progression rates for Health Assessment 
Questionnaire (HAQ) scores, the calculation 
of treatment costs and errors/omissions in the 
estimation of inpatient costs were explored. 
Some other issues were identified as potentially 
influencing model results, and the ERG carried out 
sensitivity analyses to show their impact on model 
results.
Results 
Summary of submitted 
clinical evidence
The manufacturer’s submission provides clinical 
evidence from one randomised, placebo-
controlled, double-blind trial (REFLEX – Random 
Evaluation of Long-term Efficacy of Rituximab 
in Rheumatoid Arthritis) that compares the 
effects of rituximab plus MTX with placebo plus 
MTX in a study population of 517 patients with 
long-standing refractory RA. Data from other 
randomised controlled trials (RCTs) are pooled to 
demonstrate the retreatment efficacy of rituximab 
and for the analysis of safety data. Evidence from 
a further five trials is presented as the basis for 
indirect comparisons with other disease-modifying 
antirheumatic drugs (DMARDs).
The results from the REFLEX trial at 24 and 48 
weeks confirm that rituximab plus MTX is more 
effective than placebo plus MTX (Table 1). These 
findings are consistent across a range of primary 
and secondary outcome measures including 
American College of Rheumatology (ACR) 
responses (ACR20/50/70), disease activity score 
(DAS28), European League Against Rheumatism 
(EULAR) response, HAQ, disability index (DI) and 
radiographic scores. Given that the patients in the 
trial are difficult to treat and have severe disabling 
disease with marked impairment of quality of life, 
the results of the REFLEX trial are convincing 
for this trial population. However, whether or 
not the patients in the REFLEX trial are similar 
enough to the patients described in the rituximab 
management strategies put forward in the 
manufacturer’s submission is debateable, as 40% of 
the REFLEX trial patients had received at least two 
previous TNFi before receiving rituximab.
Long-term efficacy data for retreatment with 
rituximab from the REFLEX trial are favourable, 
but the results are limited by the small number 
of patients available for follow-up. The estimated 
mean time to retreatment from the REFLEX trial is 
307 days (n = 164). The available safety data from 
the REFLEX trial show that rituximab patients 
had slightly higher rates of adverse reactions than 
the placebo patients. The European Medicines 
Evaluation Agency (EMEA) particularly stresses the 
risks of infusion reactions and infection associated 
with rituximab. This mirrors the belief that patients 
taking any of the newer biological drugs require 
close surveillance and monitoring.
The only RCT evidence available for rituximab 
is the comparison with placebo plus MTX. It is 
therefore appropriate for the manufacturer to 
conduct indirect comparisons to calculate absolute 
efficacy values for use in the economic model in 
order to answer the questions outlined in their 
statement of the decision problem. However, 
the ERG is not confident that the adjusted ACR 
scores described by the manufacturer are valid. 
In particular, it is not clear from the evidence 
presented by the manufacturer that all relevant 
clinical studies have been included in the indirect 
comparison exercise. The rationale for the choice 
of the indirect comparison method adopted is 
unclear and the indirect comparison method used 
to adjust the ACR responses only uses a single 
value for the reference placebo. 
Summary of submitted cost-
effectiveness evidence
The economic model submitted in support of the 
manufacturer’s submission is a microsimulation 
Markov model based upon the phase III RCT of 
rituximab plus MTX versus placebo plus MTX 
(REFLEX trial). Patient disease progression is 
tracked within the model according to HAQ score. 
By using microsimulation of 10,000 RA patients, 
patient history is kept in memory and cost–utility 
values are assigned to each individual at each cycle. 
The manufacturer concludes that rituximab is 
considered to be a cost-effective treatment option 
in RA. For the ‘NICE-recommended’ scenario, 
the original manufacturer’s submission reports 
an incremental cost-effectiveness ratio (ICER) Rituximab for the treatment of rheumatoid arthritis
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of £14,690 per quality-adjusted life-year (QALY) 
gained. For the ‘sequential TNFi’ scenario, the 
ICER is estimated at £11,601 per QALY gained. 
Commentary on the robustness 
of submitted evidence
The main strength of the submitted evidence is 
that the manufacturer makes a convincing case for 
the use of rituximab plus MTX versus placebo plus 
MTX using clinical evidence from the REFLEX 
trial in a specific population who are difficult to 
treat and who have severe disabling disease with 
marked impairment of quality of life. However, 
this evidence cannot be used directly to answer 
the questions raised in the manufacturer’s analysis 
of the decision problem because, in the REFLEX 
trial, rituximab was not compared with a relevant 
comparator (e.g. leflunomide or second or third 
TNFi). 
To compare the management strategies using 
rituximab described in their analysis of the decision 
problem the manufacturer carried out an indirect 
comparison exercise. However, given the criticisms 
previously outlined, the ERG is not confident that 
the adjusted ACR responses used in the economic 
evaluation are wholly valid.
TABLE 1  Key results from the REFLEX trial
Outcomea Placebo (n = 201) Rituximab (n = 298)
Primary
ACR20 (%) 24 weeks 18 51
ACR20 (%) 48 weeks 4 19
Secondary (24 weeks)
ACR50 (%) 5 27
ACR70 (%) 1 12
Change in DAS, mean (SD) –0.4 (1.17) –1.9 (1.6)
EULAR response (%):
  None 78 35
  Moderate 20 50
  Good 2 15
Change in ACR core set, mean (SD):
  Swollen joint count –2.6 (10.35) –10.4 (12.95)
  Tender joint count –2.7 (15.48) –14.4 (17.48)
  Patient global assessment –5.3 (22.88) –26.0 (29.56)
  Physician global assessment  –6.2 (27.70) –29.5 (27.40)
  Health assessment questionnaireb –0.1 (0.45) –0.4 (0.60)
  Pain assessment –2.5 (23.30) –23.4 (29.35)
  CRP (mg/dl) 0.0 (3.59) –2.1 (3.48)
  ESR (mm/hour) –4.1 (25.05) –18.5 (22.56)
Change in SF-36 domains, mean (SD):
  Mental healthc 1.3 (9.43) 4.7 (11.75)
  Physical healthd 0.9 (5.65) 5.8 (8.47)
Changes in FACIT-F,e mean (SD) –0.5 (9.84) –9.1 (11.3)
ACR, American College of Rheumatology; DAS, diseases activity score; EULAR, European League Against Rheumatism; CRP, 
C-reactive protein; ESR, erythrocyte sedimentation rate; FACIT-F, Functional Assessment of Chronic Illness Therapy-Fatigue; 
SD, standard deviation; SF-36, Short Form-36 Health Survey. 
a  For SF-36 a positive change is an improvement; for all other continuous variables a negative change is an improvement.
b  Clinically relevant improvement = decrease > 0.22.
c  Clinically relevant improvement = increase > 6.33.
d  Clinically relevant improvement = increase > 5.42.
e  Clinically relevant improvement = decrease > 4.Rituximab for the treatment of rheumatoid arthritis
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The ERG identified problems with the 
manufacturer’s submitted model in two stages. 
Early examination by the ERG of the submitted 
economic model identified some aspects of 
its implementation that caused concern as to 
its reliability for generating estimates of cost-
effectiveness. The manufacturer then submitted 
a revised model and addressed some of the 
ERG’s concerns. However, the ERG subsequently 
identified a number of additional clinical and 
economic issues that called into question the 
validity of key assumptions in the revised economic 
model, and the credibility of the ICERs generated. 
In particular, the ERG commented upon the use 
of evidence for progression rates for HAQ scores, 
the calculation of treatment costs and the estimated 
duration of effective treatment for each of the 
active agents considered.
Most importantly, the ERG questioned whether 
the size of benefit from each RA treatment is 
overstated, because loss of efficacy is assumed to 
be instantaneous rather than cumulative. The 
manufacturer’s probabilistic sensitivity analyses 
(original and revised), because of limitations 
described by the ERG, were also considered to be 
unreliable aids to decision-making.
In summary, after model assumptions were 
adjusted to more realistic estimates by the ERG, the 
ICER for the NICE-recommended scenario ranges 
from £37,002 per QALY gained to £80,198 per 
QALY gained and the ICER or the sequential use 
of TNFi ranges from £28,553 per QALY gained to 
£65,558 per QALY gained (Table 2).
Conclusions 
The consequences of the corrections and 
amendments made by the ERG demonstrate that 
the economic results for the use of rituximab no 
longer appear as unequivocally advantageous 
as suggested in the manufacturer’s submission, 
and may more reasonably be termed ‘borderline’ 
at best. There remain important areas in which 
there is substantial uncertainty, which could easily 
invalidate economic results generated by the 
manufacturer’s model, most especially in relation 
to the long-term progression of disease and its 
effect on HAQ scores, and the duration of effective 
treatment for each of the active agents considered.
The ERG concludes that the robustness of the 
evidence base used in the manufacturer’s economic 
model is uncertain. 
Summary of NICE guidance 
issued as a result of the STA 
At the time of writing the guidance issued by NICE 
(August 2007) states that: 
Rituximab in combination with methotrexate is 
recommended as an option for the treatment of 
adults with severe active rheumatoid arthritis who 
have had an inadequate response to or intolerance 
of other disease-modifying antirheumatic drugs 
(DMARDs), including treatment with at least one 
tumour necrosis factor-α (TNF-α) inhibitor therapy.
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Abstract
This paper presents a summary of the evidence 
review group (ERG) report into the clinical 
effectiveness and cost-effectiveness of omalizumab 
for the treatment of chronic severe persistent 
allergic asthma, in accordance with the licensed 
indication, based upon the evidence submission 
from Novartis to the National Institute for Health 
and Clinical Excellence (NICE) as part of the single 
technology appraisal (STA) process. The clinical 
evidence comes from a randomised controlled trial 
comparing omalizumab as an add-on to standard 
therapy with placebo and standard therapy over 
a 28-week treatment period. For the primary 
outcome of the rate of clinically significant asthma 
exacerbations, there was no statistically significant 
difference between treatment groups. However, 
after making a post hoc adjustment for a suggested 
‘clinically relevant’ imbalance between trial arms 
in baseline exacerbation rate, the difference 
became marginally statistically significant. In terms 
of secondary outcomes, there were statistically 
significant differences favouring omalizumab over 
placebo in total emergency visits, Asthma Quality 
of Life Questionnaire scores, total symptom scores 
and lung function. Adverse events appeared to 
be similar between the trial arms. Results from 
three other publications are included in the 
manufacturer’s submission as supporting evidence 
for the effectiveness of omalizumab, despite not 
meeting the inclusion criteria which adhere strictly 
to the licensed indication. The ERG checked and 
provided commentary on the manufacturer’s 
model using standard checklists as well as 
undertook one-way sensitivity analysis, scenario 
analysis and a probabilistic sensitivity analysis. 
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The cost-effectiveness analysis estimates the 
incremental costs and consequences of omalizumab 
as an add-on to standard therapy. The base-case 
analysis of the trial’s primary intention-to-treat 
population estimates a cost per quality-adjusted 
life-year of £30,647. The ERG conducted one-way 
sensitivity analyses for parameters omitted from 
the manufacturer’s submission sensitivity analysis. 
The results were most sensitive to variation in the 
utility values for omalizumab responders, and the 
unit cost of omalizumab. The guidance issued by 
NICE in November 2007 as a result of the STA 
states that omalizumab is recommended as a 
possible treatment for adults and young people 
over 12 years with severe persistent allergic asthma 
when their asthma meets certain conditions. 
Omalizumab treatment should be given along with 
the person’s current asthma medicines. It should 
be prescribed by a doctor who is experienced in 
asthma and allergy medicine at a specialist centre. 
If omalizumab does not control the asthma after 16 
weeks, treatment should be stopped.
Introduction
The National Institute for Health and Clinical 
Excellence (NICE) is an independent organisation 
within the NHS which is responsible for providing 
national guidance on the treatment and care of 
people using the NHS in England and Wales. 
One of the responsibilities of NICE is to provide 
guidance to the NHS on the use of selected new 
and established health technologies, based on an 
appraisal of those technologies.
NICE’s single technology appraisal (STA) process 
is specifically designed for the appraisal of a single 
product, device or other technology, with a single 
indication, where most of the relevant evidence 
lies with one manufacturer or sponsor.1 Typically, 
it is used for new pharmaceutical products close 
to launch. The principal evidence for an STA is 
derived from a submission by the manufacturer/
sponsor of the technology. In addition, a report 
reviewing the evidence submission is submitted 
by the evidence review group (ERG); an external 
organisation independent of NICE. This paper 
presents a summary of the ERG report for the STA, 
omalizumab for severe persistent allergic asthma.
Description of the underlying 
health problem
Asthma is characterised by symptoms such as 
dyspnoea, chest tightness, wheezing and cough 
associated with variable airflow obstruction and 
airway hyper-responsiveness. The development of 
asthma occurs when a person comes into contact 
with a trigger; the bronchioles (small airways in the 
lungs) become inflamed, swollen and constricted 
and excess mucus is produced, which has an effect 
on the person’s airway structure and function.
Asthma attacks vary in frequency and severity. 
Some people who have asthma are mostly 
symptom-free, with only occasional episodes 
of shortness of breath. Other people cough 
and wheeze most of the time and may have 
severe attacks after viral infections, exercise or 
irritants, including cigarette smoke; however, 
the absence of a cough or wheeze does not mean 
the attack is not severe. Asthma can have an 
allergic component resulting in overproduction 
of human immunoglobulin E (IgE) in response 
to environmental allergens, e.g. pollen, house 
dust mite. IgE binds to cell membrane receptors, 
resulting in the release of inflammatory mediators.
There are approximately 5.2 million people with 
asthma in the UK (4.7 million in England and 
Wales). The total for the UK includes 590,000 
teenagers with asthma. Approximately 5% of 
asthma patients have severe asthma.
Current British guidelines from the British 
Thoracic Society (BTS) and Scottish Intercollegiate 
Guidelines Network (SIGN) recommend a stepwise 
approach to treatment.2 Control is maintained by 
stepping up treatment as necessary and stepping 
down when control is good.
Scope of the evidence 
review group report
The ERG critically evaluated the evidence 
submission from Novartis on the use of 
omalizumab for the treatment of chronic severe 
persistent allergic asthma.
Omalizumab has a marketing authorisation for 
add-on therapy to improve asthma control in adult 
and adolescent patients (12 years of age and above) 
with severe persistent allergic asthma and ALL of 
the following:
•	 a positive skin test or in vitro reactivity to a 
perennial aeroallergen
•	 reduced lung function (forced expiratory 
volume in 1 second; FEV1 < 80%), frequent 
daytime symptoms or night-time awakenings, 
multiple documented severe asthma 
exacerbations despite daily high-dose inhaled 
corticosteroids (ICS), plus a long-acting 
inhaled beta2-agonist (LABA)Health Technology Assessment 2009; Vol. 13: Suppl. 2
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•	 convincing IgE-mediated asthma.
The intervention specified in the decision problem 
was omalizumab as an add-on therapy to standard 
therapy, used within its licensed indication. The 
comparator was treatment without omalizumab. 
This means standard treatment such as ICS in 
combination with LABA, plus other medication 
as necessary in accordance with the BTS/SIGN 
guidelines. The population was adults and 
adolescent patients (12 years of age and above) 
with severe persistent allergic asthma under the 
conditions specified in the marketing authorisation. 
The outcome measures included objective measures 
of lung function [e.g. FEV1, peak expiratory flow 
(PEF)], symptom-free days and nights, incidence of 
acute exacerbations (e.g. unscheduled contact with 
health-care professional; hospitalisation or visit to 
accident and emergency department), levels of ICS, 
use of oral corticosteroids, reduction in IgE levels, 
adverse effects of treatment, health-related quality 
of life and mortality.
Methods
The ERG report comprised a critical review of 
the evidence for the clinical evidence and cost-
effectiveness of the technology based upon the 
manufacturer’s/sponsor’s submission to NICE as 
part of the STA process.
The ERG checked the literature searches and 
applied the NICE critical appraisal checklist to 
the included studies and checked the quality of 
the manufacturer’s submission with the Centre 
for Reviews and Dissemination (CRD) quality 
assessment criteria for a systematic review. 
In addition, the ERG checked and provided 
commentary on the manufacturer’s model using 
standard checklists. A one-way sensitivity analysis, 
scenario analysis and a probabilistic sensitivity 
analysis were undertaken by the ERG.
Results
Summary of submitted 
clinical evidence
The manufacturer’s submission presents clinical 
evidence for omalizumab in patients with severe 
persistent allergic asthma based on one published 
multicentre international double-blind randomised 
controlled trial (RCT) [known as the Investigation 
of Omalizumab in Severe Asthma Treatment 
(INNOVATE) trial].3 (Table 1) This was the 
pivotal EU/UK licensing trial. The trial compares 
omalizumab as an add-on to standard therapy (e.g. 
ICS and LABA) with placebo and standard therapy 
over a 28-week treatment period.
The efficacy analyses were carried out on the 
‘primary intention to treat’ (PITT) population, 
which excludes 13% of randomised patients 
(excluded due to a trial protocol amendment). 
With the exception of safety results, ‘true’ intention 
to treat (ITT) results are not reported in the 
main manufacturer’s submission report, or the 
INNOVATE journal publication. For the primary 
outcome of the rate of clinically significant asthma 
exacerbations, there was no statistically significant 
difference between treatment groups. However, 
after making a post hoc adjustment for a suggested 
‘clinically relevant’ imbalance between trial arms in 
baseline exacerbation rate, the difference became 
marginally statistically significant.
In terms of secondary outcomes, there were 
statistically significant differences favouring 
omalizumab over placebo in total emergency visits, 
Asthma Quality of Life Questionnaire scores, total 
symptom scores and lung function. Adverse events 
appeared to be similar between the trial arms.
Results from three other publications are included 
in the manufacturer’s submission as supporting 
evidence for the effectiveness of omalizumab, 
despite not meeting the inclusion criteria which 
adhere strictly to the licensed indication. These 
included a 12-month open-label ‘naturalistic’ RCT, 
a meta-analysis of seven pharmaceutical company 
sponsored trials, and a Cochrane systematic review 
of 14 RCTs of anti-IgE treatment. The results of 
these publications, in differing populations of 
asthmatics (e.g. mild to moderate asthma), are 
reported to support the findings of the INNOVATE 
trial.
Summary of submitted cost-
effectiveness evidence
The cost-effectiveness analysis (CEA) comprises 
a Markov state-transition model to estimate the 
incremental costs and consequences of omalizumab 
as an add-on to standard therapy. The model 
has been applied in a published Swedish4 and 
a published Canadian5 cost-effectiveness study 
and is reported to have been validated by asthma 
physicians and modelling experts.
Despite some limitations in reporting, the model 
is, in general, internally consistent and appropriate 
to severe asthma in terms of its structural 
assumptions. The CEA generally conforms to Omalizumab for the treatment of severe persistent allergic asthma
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the NICE reference case and the scope/decision 
problem.
The model assumes that responders to omalizumab 
(those rated as ‘excellent’ or ‘good’ using the 
global evaluation of treatment effectiveness) at 16 
weeks will continue to receive the drug for 5 years, 
after which they revert to standard therapy. Non-
responders to omalizumab at 16 weeks revert to 
standard therapy at that point. The model has a 
lifetime horizon.
Data from the INNOVATE trial are used to 
estimate the proportion of patients with clinically 
significant exacerbations (both severe and non-
severe), the utility associated with day-to-day 
symptoms, and treatment costs. Utility values for 
clinically significant exacerbations were taken from 
another study.6
The base-case analysis of the INNOVATE PITT 
population estimates a cost per quality-adjusted 
life-year (QALY) of £30,647. The base-case cost 
per QALY for a subgroup of ‘high risk’ patients 
hospitalised in the previous year was £26,509.
The base-case estimate for the INNOVATE PITT 
population rises as the mortality rate associated 
with clinically severe exacerbations decreases, with 
a cost per QALY of £73,177 when a 0% rate is used.
The ERG conducted one-way sensitivity analyses 
for parameters omitted from the manufacturer’s 
submission sensitivity analysis. The results were 
most sensitive to variation in the utility values 
for omalizumab responders, and the unit cost of 
omalizumab.
The ERG conducted scenario analyses examining 
the cumulative effect of varying assumptions over 
the asthma mortality rate, costing of omalizumab, 
and utilities applied to the exacerbation states 
and to the day-to-day symptoms state for standard 
care. Using a lower mortality rate than in the 
base case and a more realistic approach to costing 
omalizumab in primary care produced less 
favourable incremental cost effectiveness ratios 
(ICERs) than in the base case. ICERs were more 
sensitive to assumptions over the difference in 
utility between omalizumab responders and 
standard care/non-responders than to utility 
associated with transient changes (such as 
exacerbations).
The probabilistic cost–utility analysis of the 
INNOVATE PITT population was £31,713 
(confidence interval £23,178, £48,236) with a 50% 
probability of the ICER being under £32,000. A 
replication of the probabilistic analysis by the ERG 
using a lower mortality rate (2%) and omalizumab 
cost per vial rather than per milligram, generated 
a mean ICER of £38,852. At a threshold willingness 
to pay of £30,000 per QALY, omalizumab add-on 
therapy has a 23.6% probability of being cost-
effective (Figure 1 and Figure 2).
Commentary on the robustness 
of submitted evidence
Strengths
The manufacturer’s submission includes a 
systematic search for clinical effectiveness and cost-
effectiveness studies of omalizumab. It appears 
unlikely that any additional trials would have met 
the inclusion criteria had the search been widened 
to include other databases.
The INNOVATE trial appears to be of reasonable 
methodological quality (with some limitations – see 
below) and measures a range of clinically relevant 
outcomes (e.g. exacerbations, day and night 
symptoms, health-related quality of life, emergency 
visits and adverse events). Taken together these 
outcomes accurately capture the impact of 
pharmacotherapy on the control of severe asthma.
The economic model appears internally consistent 
and structurally appropriate, and the cost-
effectiveness analysis is in accordance with the 
NICE reference case and the scope of the appraisal.
Weaknesses
Despite a systematic search and screen of the 
literature, only one RCT was included. The 
manufacturer’s submission is therefore largely 
dependent upon this one trial. Although the trial 
has merits there are also weaknesses, notably in 
the statistical analysis. Further high-quality RCT 
evidence for the effectiveness of omalizumab in 
the patient group meeting the licensed indication 
would be beneficial.
The INNOVATE trial was subject to protocol 
amendments which resulted in the exclusion of 
13% of randomised patients from the PITT efficacy 
population (although it is reported that the results 
of the full ITT analysis are similar to the PITT).
As acknowledged in the manufacturer’s submission, 
there was a strong placebo effect in the INNOVATE 
trial, exemplified by the relatively high physician 
rating of response for patients receiving placebo 
in addition to standard therapy. This is attributed 
to the optimised standard of care received by Health Technology Assessment 2009; Vol. 13: Suppl. 2
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FIGURE 2  Cost-effectiveness acceptability curve from ERG probabilistic sensitivity analysis, INNOVATE primary intention-to-treat 
population.
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FIGURE 1  Scatter plot of the ERG probabilistic sensitivity analysis results. QALYs, quality-adjusted life-years.
patients in the clinical trial. Consequently, the 
manufacturer’s submission regards the treatment 
effect to be an underestimate. Although an 
open-label RCT conducted in a setting more 
representative of clinical practice was presented 
as supporting evidence, only around half of the 
randomised patients in this trial met the criteria 
for the licensed indication.Omalizumab for the treatment of severe persistent allergic asthma
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Conclusions
Areas of uncertainty
There is uncertainty about some of the statistical 
methods used in the analysis of the INNOVATE 
trial because of post hoc adjustments to the 
primary outcome to correct for suggested clinically 
relevant imbalances in baseline exacerbation 
history between trial arms. The manufacturer’s 
submission reports that such adjustment was 
recommended by the Committee for Medicinal 
Products for Human Use. The validity of post 
hoc adjustments has to be viewed with caution, 
particularly as the difference in favour of 
omalizumab in the primary outcome only became 
statistically significant following adjustment.
The validity of including unpublished post hoc 
analysis for two subgroups (‘high-risk’ previously 
hospitalised patients, and omalizumab responders), 
is also questionable as both are likely to be 
underpowered.
Long-term published data on the effectiveness and 
safety of omalizumab are not yet available. The 
economic model extrapolates efficacy data from the 
28-week INNOVATE trial over a 5-year period, and 
assumes full compliance. In practice, compliance 
is likely to vary with factors such as the standard 
of care, which may not be as optimal as within the 
context of a clinical trial.
There is no discussion in the manufacturer’s 
submission of possible bias introduced due 
to missing response data on 14 omalizumab-
treated patients. There is no discussion of 
the characteristics of these patients and the 
manufacturer’s submission does not report the 
number of exacerbations for these patients 
separately.
The submission assumes that it is possible to 
store unused portions of vials of omalizumab and 
therefore costs the drug by the milligram rather 
than by the vial. It is unclear whether such a policy 
of re-use would be feasible in primary care, without 
incurring substantial additional costs for safe 
storage and managing this process.
There is substantial uncertainty over the excess 
mortality rate applied to severe exacerbations 
in the model. The rate used was derived from a 
Swedish observational study7 in which definitions 
of severe and moderate asthma exacerbations were 
not clearly specified, and the patient population 
was substantially older (62.5 years) than the 
mean starting age for patients in the model (40 
years). The manufacturer’s submission contains 
no discussion or objective evidence on the extent 
to which the dimension that defines a clinically 
significant exacerbation as severe in the model 
(PEF or FEV1 less than 60% of personal best) is a 
valid predictor of risk of asthma death.
Key issues
Given that the inclusion criteria adhere strictly to 
the licensed indication, only one RCT was officially 
included in the manufacturer’s submission (the 
pivotal licensing trial). In this trial the primary 
outcome became statistically significant in favour 
of omalizumab only once a post hoc adjustment 
had been made to correct for a ‘clinically relevant’ 
imbalance between trial arms.
The ICER is highly sensitive to assumptions 
about the mortality rate associated with severe 
exacerbations, and to a lesser extent to whether 
omalizumab is costed on a per vial or per 
milligram basis.
Summary of NICE guidance 
issued as a result of the STA
The guidance issued by NICE in November 2007, 
TA133, states that:
Omalizumab is recommended as a possible 
treatment for adults and young people over 12 
years with severe persistent allergic asthma when all 
of the following circumstances apply.
•	 When the person’s asthma is still severe and 
unstable despite best efforts to control it with 
other asthma medicines taken as directed by 
their doctor.
•	 When the person has stopped smoking, if their 
doctor feels it is appropriate.
•	 When the person has allergic asthma. This 
should be confirmed by checking past 
symptoms and skin testing for allergies.
•	 When the person has had at least two asthma 
attacks within the past year that have needed 
admission to hospital, or when the person 
has had three or more severe asthma attacks 
within the past year, one of which has needed 
admission to hospital and the other two have 
needed additional treatment in an accident 
and emergency department.
Omalizumab treatment should be given along with 
the person’s current asthma medicines. It should 
be prescribed by a doctor who is experienced in Health Technology Assessment 2009; Vol. 13: Suppl. 2
© 2009 Queen’s Printer and Controller of HMSO. All rights reserved.
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asthma and allergy medicine at a specialist centre. 
If omalizumab does not control the asthma after 16 
weeks, treatment should be stopped.
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Abstract
This paper presents a summary of the evidence 
review group report into the clinical effectiveness 
and cost-effectiveness of rituximab for the 
treatment of relapsed or refractory stage III or 
IV follicular non-Hodgkin’s lymphoma (NHL), 
in accordance with the licensed indication, based 
upon the evidence submission from Roche Products 
Ltd to the National Institute for Health and 
Clinical Excellence (NICE) as part of the single 
technology appraisal (STA) process. The submitted 
clinical evidence included two randomised 
controlled trials [European Organisation for 
Research and Treatment of Cancer (EORTC) and 
German Low Grade Lymphoma Study Group – 
Fludarabine, Cyclophosphamide and Mitoxantrone 
and (GLSG-FCM)] comparing the clinical effects 
of chemotherapy with or without rituximab in the 
induction of remission at first or second relapse 
and the clinical benefits of rituximab maintenance 
therapy versus the NHS’s current clinical practice 
of observation for follicular lymphoma (FL) 
patients. Both trials showed that in patients 
with relapsed FL the addition of rituximab to 
chemotherapy induction treatment increased 
overall response rates. Furthermore, rituximab 
maintenance therapy increased the median length 
of remission when compared with observation only. 
Safety data from the two trials showed that while 
the majority of patients reported some adverse 
events, the number of patients withdrawing from 
treatment in the EORTC trial was low, with rates 
not being reported for the GLSG-FCM trial. 
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The most commonly reported adverse events 
were blood/bone marrow toxicity, skin rashes 
and allergies. The ERG reran the manufacturer’s 
economic model after altering several of the 
assumptions and parameter values in order to 
recalculate the cost–utility ratios, quality-adjusted 
life-years (QALYs) and estimates of benefits. The 
manufacturer reported that maintenance therapy 
with rituximab was cost-effective compared with 
observation against commonly applied thresholds, 
with an incremental cost-effectiveness ratio of 
£7721 per QALY gained. The greatest clinical 
effectiveness is achieved by R-CHOP followed by 
rituximab maintenance (R-CHOP>R) and this 
treatment strategy had the greatest probability of 
being cost-effective for a QALY of approximately 
£18,000 or greater. The guidance issued by 
NICE as a result of the STA states that in people 
with relapsed stage III or IV follicular NHL, 
rituximab is now an option in combination with 
chemotherapy to induce remission or alone as 
maintenance therapy during remission. Rituximab 
monotherapy is also an option for people with 
relapsed or refractory disease when all alternative 
treatment options have been exhausted.
Introduction
The National Institute for Health and Clinical 
Excellence (NICE) is an independent organisation 
within the NHS that is responsible for providing 
national guidance on the treatment and care of 
people using the NHS in England and Wales. 
One of responsibilities of NICE is to provide 
guidance to the NHS on the use of selected new 
and established health technologies, based on an 
appraisal of those technologies.
NICE’s single technology appraisal (STA) process 
is specifically designed for the appraisal of a single 
product, device or other technology, with a single 
indication, where most of the relevant evidence 
lies with one manufacturer or sponsor.1 Typically, 
it is used for new pharmaceutical products close 
to launch. The principal evidence for an STA is 
derived from a submission by the manufacturer/
sponsor of the technology. In addition, a report 
reviewing the evidence submission is submitted 
by the evidence review group (ERG); an external 
organisation independent of the Institute. This 
paper presents a summary of the ERG report for 
the STA entitled ‘Rituximab for the treatment of 
relapsed or refractory stage III or IV follicular non-
Hodgkin’s lymphoma’.2
Description of the underlying 
health problem
Non-Hodgkin’s lymphoma (NHL) represents 
about 3% of all cancers diagnosed in the UK. In 
2002 there were 9443 people diagnosed with NHL 
in the UK3 with an incidence of 16 per 100,000 
in England and 15.6 per 100,000 in Wales. The 
overall rate is increasing at 3–4% per year, which 
is greater than would be expected from simply a 
combination of the effects of an ageing population 
plus improved diagnostic techniques.4 Follicular 
lymphoma (FL) is the second most common type of 
NHL (22%) with a UK incidence of approximately 
4 per 100,0005 and a prevalence of about 40 per 
100,000.4,5
Low-grade or indolent disease is differentiated 
from high-grade or aggressive disease by histology. 
Histological grading of the disease is determined 
by the World Health Organization classification 
grades I, II or IIIa or IIIb.5 The grade is 
determined by the number and size of abnormal 
cells taken from lymph node biopsies. There is a 
growing consensus that histological grade III and, 
in particular, grade IIIb disease should be classified 
as aggressive and treated as such rather than 
treated as indolent disease.
Survival for patients with FL is prolonged. Different 
figures for median survival have been reported, but 
8–10 years from diagnosis is typical.6,7 However, 
these are likely to be underestimates as there is 
good evidence from recent large population-based8 
and single institution studies9,10 that survival is 
improving.11 This is probably as a consequence of 
improved treatment, especially the introduction of 
rituximab, which is the first drug treatment for this 
disease to demonstrate an ability to improve overall 
survival in randomised controlled trials.
Scope of the evidence 
review group report
The ERG report presents the results of the 
assessment of the manufacturer’s/sponsor’s 
evidence submission regarding the use of rituximab 
for the treatment of relapsed/refractory FL. 
The ERG report includes an assessment of both 
the clinical and the cost-effectiveness evidence 
submitted by Roche Products Limited. The 
manufacturer’s submission (MS) considers two 
ways of using rituximab: firstly, in conjunction 
with cytotoxic chemotherapy in order to induce 
remission in relapsed FL; and secondly, as 
maintenance therapy after successful induction of 
remission, regardless of the chemotherapy used 
to induce remission. The manufacturer presents Health Technology Assessment 2009; Vol. 13: Suppl. 2
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clinical evidence to support the use of (1) rituximab 
plus chemotherapy (e.g. R-CHOP and R-FCM) 
in the induction phase and (2) rituximab versus 
observation in the maintenance phase of treatment 
for FL patients. Only clinical evidence from the 
CHOP comparisons is used in the cost-effectiveness 
analyses. The MS claims that there is no new 
evidence for the use of rituximab in adult patients 
with stage III–IV FL who are chemoresistant or 
are in their second or subsequent relapse after 
chemotherapy. Therefore the MS presents no 
new case for the use of rituximab in this patient 
population.
Methods
The ERG report comprised a critical review 
of the clinical and cost-effectiveness evidence 
presented in the MS to NICE as part of the STA 
process. The ERG assessed the quality of the 
clinical effectiveness review using a checklist, and 
attempted to replicate relevant clinical effectiveness 
and cost-effectiveness literature searches. The ERG 
re-ran the manufacturer’s economic model after 
altering several of the assumptions and parameter 
values in order to recalculate the cost–utility ratios, 
quality-adjusted life-years (QALYs) and estimates of 
benefits.
Results
Summary of submitted 
clinical evidence
The MS provides clinical evidence from two 
randomized controlled trials (EORTC and GLSG-
FCM). Both trials were included in the clinical 
systematic review and compare the clinical effects 
of chemotherapy with or without rituximab in the 
induction of remission at first or second relapse, 
and the clinical benefits of rituximab maintenance 
therapy versus the NHS’s current clinical practice 
of observation for FL patients. Both trials had two 
points of randomisation. The induction phases 
included 465 and 147 patients with relapsed FL 
in EORTC and GLSG-FCM trials respectively. 
The maintenance phases included 395 and 176 
patients who had responded to induction therapy 
in EORTC and GLSG-FCM trials respectively. 
Only 113 patients in the GLSG-FCM trial who 
received maintenance therapy or observation were 
FL patients. Both trials showed that in patients 
with relapsed FL the addition of rituximab to 
chemotherapy induction treatment increased 
overall response rates; 72.3% (CHOP) versus 
85.1% (R-CHOP) in the EORTC trial and 70% 
(FCM) versus 94% (R-FCM) in the GLSG-FCM 
trial. Furthermore, rituximab maintenance therapy 
increased the median length of remission when 
compared with observation only. In the EORTC 
trial, median progression-free survival (PFS) was 
14.9 months for those on observation compared 
with 51.5 months for those receiving rituximab. In 
the GLSG-FCM trial for FL patients who received 
R-FCM, median PFS in the observation group 
was 26 months, and for those receiving rituximab 
median PFS was not reached.
Safety data from the two trials showed that while 
the majority of patients reported some adverse 
events, the number of patients withdrawing from 
treatment in the EORTC trial was low: 3% in each 
group at induction and 4% in the rituximab group 
at maintenance (rates were not reported for the 
GLSG-FCM trial). The most commonly reported 
adverse events were blood/bone marrow toxicity, 
skin rashes and allergies.
Summary of submitted cost-
effectiveness evidence
The MS presents the results of two sets of 
economic evaluations. The first compares the use 
of rituximab maintenance (following response 
to an induction therapy) with observation only 
(no treatment until relapse). This is referred to 
as the maintenance two-arm model. A three-state 
transition model (progression free, progressive 
disease and death) is used to capture the costs and 
benefits of relapsed/refractory FL.
The second model compares the use of rituximab 
maintenance therapy with observation only for 
patients responding to chemotherapy with or 
without rituximab, and tests whether the use of 
rituximab as an induction therapy in addition 
to maintenance therapy is cost-effective. This is 
referred to as the induction plus maintenance 
four-arm model. A five-state transition model 
(progression free in the induction setting, 
progression free in the maintenance setting, 
progression free but not in the induction or 
maintenance setting, progressive disease and 
death) captures the costs and benefits of relapsed/
refractory FL.
Evidence from the EORTC trial is the principal 
source of clinical data used in the economic 
evaluations. A half-cycle correction is applied in 
both models. Patients in the economic evaluation 
are followed through the health states in monthly 
cycles over a period of 30 years in order to 
capture the entire lifetime costs and effects of the Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma
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population. Patients only exit the model due to 
death.
In the MS, the two-arm model is used to 
demonstrate that maintenance therapy with 
rituximab when compared with observation is cost-
effective against commonly applied thresholds. 
The manufacturer reports an incremental cost-
effectiveness ratio (ICER) of £7721 per QALY 
gained for this comparison. In the MS, when 
subject to extensive univariate and probabilistic 
sensitivity analysis (PSA), this ICER is shown 
to be robust (Table 1). In the MS, the four-arm 
economic model illustrates that the greatest clinical 
effectiveness is achieved by R-CHOP followed 
by rituximab maintenance (R-CHOP>R). The 
MS concludes that R-CHOP>R is cost-effective 
when compared with the second most clinically 
effective intervention of CHOP induction followed 
by rituximab maintenance therapy (CHOP>R); 
the estimated ICER is £16,749 per QALY gained. 
Again, in the MS this ICER is shown to be robust 
(Table 2).
For the PSA, scatter plots and cost-effectiveness 
acceptability curves were calculated. For the four-
arm model, the manufacturer presents a scatter 
plot to illustrate the considerable overlap of costs 
and QALYs across the four treatment groups (Figure 
1). The cost-effectiveness acceptability curve shows 
that at a willingness to pay (WTP) for a QALY of 
approximately £18,000 or greater, the R-CHOP>R 
treatment strategy had the greatest probability of 
being cost-effective (Figure 2).
Commentary on the robustness 
of submitted evidence
Strengths
The MS includes supporting clinical data from 
two randomised controlled trials, both of which 
closed early due to interim analyses showing a 
significant clinical benefit for rituximab treatment 
as induction and/or maintenance therapy before 
enrolment was complete.
The two economic models submitted by the 
manufacturer are implemented to a generally 
high standard, clearly presented and with a large 
amount of source information included to aid 
traceability. The layouts of the various elements of 
the models are generally logical, and the formulae 
employed are straightforward.
Weakness
The systematic review (SR) reported in the MS 
does not clearly specify the inclusion and exclusion 
criteria employed, which results in ambiguity 
regarding reasons for the exclusion of some trials. 
In addition, the MS fails to describe adequately the 
existing clinical evidence for the use of rituximab 
monotherapy in the treatment of relapsed FL.
The GLSG-FCM trial includes FL, mantle cell and 
lymphocytoid lymphoma patients. Evidence to 
support the use of rituximab as maintenance from 
the GLSG-FCM trial is inconclusive due to missing 
clinical data for FL patients only.
TABLE 1  Incremental cost-effectiveness of rituximab maintenance compared with observation
Treatment group Total costs QALYs gained
Incremental cost per 
QALY gained
Rituximab  £21,608 4.2250
‘Observation’ £14,722 3.3331
Incremental  £6886 0.8919 £7721
QALY(s), quality-adjusted life-years(s).
TABLE 2  Incremental cost-effectiveness of a treatment strategy of R-CHOP>R versus a treatment strategy of CHOP>R in patients 
presenting for induction therapy
Treatment and 
comparator groups Costs QALYs gained
Incremental cost per 
QALY gained
R-CHOP>R £28,585 4.0906
CHOP>R £22,389 3.7207
Incremental £6196 0.3699 £16,749
QALY(s), quality-adjusted life-years(s).Health Technology Assessment 2009; Vol. 13: Suppl. 2
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FIGURE 1  Scatter plot showing incremental cost and effect of maintenance therapy over CHOP>observation across 2000 simulations of 
the economic model.
FIGURE 2  Cost-effectiveness acceptability curve – probability that each treatment practice is cost-effective at a given willingness-to-pay 
(WTP) threshold.
From the available clinical evidence, the ERG 
concludes that the maintenance two-arm economic 
model is too simplistic and therefore the ERG 
concentrates on the results generated by the 
induction plus maintenance four-arm model.
Uncertainty
The clinical effectiveness of R-CHOP induction 
in patients previously treated with rituximab 
cannot be assessed from this STA as patients in 
the EORTC trial are rituximab naive at entry. In Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma
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2006, R-CVP was approved by NICE12 as a first-
line treatment for patients with FL. It is therefore 
unlikely that future patients with relapsed FL in the 
NHS in England and Wales will be rituximab naive.
The ERG raised some concerns about the 
modelling of the survival data. The ERG was 
unable to overcome such concerns (e.g. by 
conducting PSA) as the manufacturer did not 
provide the requested additional information on 
the disposition of patients in the EORTC trial 
and the mean time spent in each segment of the 
treatment pathway.
Conclusions
The ERG acknowledges that the economic models 
submitted by the manufacturer are implemented 
to a generally high standard, clearly presented and 
with a large amount of source information included 
to aid traceability. The layouts of the various 
elements of the models are generally logical, and 
the formulae employed are straightforward.
On detailed examination of the models, the ERG 
identified a minor anomaly in the model coding 
that affected estimates of both costs and outcomes. 
Correction of this anomaly favoured the rituximab 
patients. In terms of costs, the ERG made two 
adjustments which increased the R-CHOP>R 
versus CHOP>R ICER. Firstly, the outpatient cost 
(£86) is replaced by a chemotherapy administration 
cost (£504) in order to reflect that demanding 
chemotherapy regimens are typically given within 
a day-case setting and the ICER increases from 
£16,749 to £18,204. Secondly, the calculation of 
alternative postprogression treatment costs by 
the ERG also increases the ICER from £16,749 to 
£22,688.
In terms of utilities, changing the postprogression 
utility values does not have a major impact on 
the ICERs. However, the preferred approach to 
survival modelling does impact on the size of 
the ICER for every possible combination in the 
four-arm model. The ERG identifies four areas of 
concern regarding the manufacturer’s estimation 
of lifetime benefits from use of rituximab. In order 
to overcome such concerns, the ERG requested 
additional information from the manufacturer 
about the disposition of patients and the mean 
time spent in each segment of the treatment 
pathway. The manufacturer declined to provide 
this information. Consequently, the ERG used the 
observed and reported evidence on PFS and overall 
survival (OS) from the EORTC trial rather than the 
manufacturer’s projections. In doing so, the ICERs 
for the six possible combinations now range from 
£13,895 to £73,140.
The ERG calculated the cumulative effect of all 
of the changes on the ICERs (Table 3). It is clear 
that the single-use strategies are the most cost-
effective options, i.e. use of rituximab for induction 
of remission (£13,122 per QALY gained) or for 
maintenance of remission (£16,488 per QALY 
gained). Dual-use strategies compared with single-
use strategies are the least cost-effective options at 
around £42,000 per QALY gained. A comparison 
of dual use of rituximab with no use of rituximab 
also appears to be moderately cost-effective 
(£26,000 per QALY gained). However, in order to 
fully inform decision-making about the preferred 
use of rituximab for FL, a comprehensive PSA in 
the form of a cost-effectiveness acceptability plot 
is required. However, as all of the necessary data 
were not available to the ERG, it was not possible to 
carry out this assessment.
In summary, the ERG agrees that the use of 
rituximab for the treatment of FL is probably cost-
effective, but cannot confidently recommend either 
or both single-use strategies over the dual-use 
strategy, based on the available data.
Summary of NICE guidance 
issued February 2008 as 
a result of the STA
In people with relapsed stage III or IV follicular 
NHL, rituximab is now an option in combination 
with chemotherapy to induce remission or alone as 
maintenance therapy during remission. Rituximab 
monotherapy is also an option for people with 
relapsed or refractory disease when all alternative 
treatment options have been exhausted.
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Abstract
This paper presents a summary of the evidence 
review group (ERG) report into the clinical and 
cost-effectiveness of adalimumab for the treatment 
of moderate to severe plaque psoriasis based 
upon a review of the manufacturer’s submission 
to the National Institute for Health and Clinical 
Excellence (NICE) as part of the single technology 
appraisal (STA) process. The submission’s clinical 
evidence came from three randomised controlled 
trials comparing adalimumab with placebo, two 
extension studies and one ongoing open-label 
extension study. The studies were of reasonable 
quality and measured a range of clinically relevant 
outcomes.  A higher proportion of patients on 
40 mg adalimumab every other week achieved an 
improvement on the Psoriasis Area and Severity 
Index (PASI) of at least 75% (PASI 75) compared 
with placebo groups after 12 or 16 weeks of 
treatment, and there was a statistically significant 
difference in favour of adalimumab for the 
proportion of patients achieving a PASI 50 and 
a PASI 90. In a mixed treatment comparison, for 
each PASI outcome the probability of a response 
was greater for infliximab than for adalimumab, 
but the probability of response with adalimumab 
was greater than that with etanercept, efalizumab 
and non-biological systemic therapies. Adverse 
event rates were similar in the treatment and 
placebo arms and discontinuations because of 
adverse events were low and comparable between 
groups. The submission’s economic model presents 
treatment effectiveness for adalimumab versus 
other biological therapies based upon utility values 
obtained from two clinical trials. The model is 
generally internally consistent and appropriate to 
psoriasis in terms of structural assumptions and 
the methods used are appropriate. The base-case 
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incremental cost-effectiveness ratio for adalimumab 
compared with supportive care for patients with 
severe psoriasis was £30,538 per quality-adjusted 
life-year. Scenario analysis shows that the model 
was most sensitive to the utility values used. 
Weaknesses of the clinical evidence included not 
undertaking a systematic review of the comparator 
trials, providing very little in the way of a narrative 
synthesis of outcome data from the key trials and 
not performing a meta-analysis so that the overall 
treatment effect of adalimumab achieved across 
the trials is unknown. Weaknesses of the economic 
model included that the assumptions made to 
estimate the cost-effectiveness of intermittent 
etanercept used inconsistent methodology for 
costs and benefits and there were no clear data 
on the amount of inpatient care required under 
supportive care. The NICE guidance issued as 
a result of the STA states that adalimumab is 
recommended as a treatment option for adults 
with plaque psoriasis in whom anti-tumour necrosis 
factor treatment is being considered and when the 
disease is severe and when the psoriasis has not 
responded to standard systemic therapies or the 
person is intolerant to or has a contraindication to 
these treatments.
Introduction 
The National Institute for Health and Clinical 
Excellence (NICE) is an independent organisation 
within the NHS that is responsible for providing 
national guidance on the treatment and care of 
people using the NHS in England and Wales. 
One of the responsibilities of NICE is to provide 
guidance to the NHS on the use of selected new 
and established health technologies, based on an 
appraisal of those technologies.
NICE’s single technology appraisal (STA) process 
is specifically designed for the appraisal of a single 
product, device or other technology, with a single 
indication, for which most of the relevant evidence 
lies with one manufacturer or sponsor.1 Typically, 
it is used for new pharmaceutical products close 
to launch. The principal evidence for an STA is 
derived from a submission by the manufacturer/
sponsor of the technology. In addition, a report 
reviewing the evidence submission is submitted 
by the evidence review group (ERG), an external 
organisation independent of NICE. This paper 
presents a summary of the ERG report for the STA 
of adalimumab for the treatment of psoriasis.
Description of the 
underlying health problem
Psoriasis is an inflammatory skin disease that can 
take several forms. The most common type is 
plaque psoriasis, characterised by exacerbations of 
thickened, erythematous, scaly patches of skin that 
can occur anywhere on the body. The severity of 
psoriasis can vary from mild through to moderate 
and severe. The disease impacts on quality of life at 
all levels of disease severity.
It is well recognised that obtaining estimates for 
psoriasis prevalence is difficult. NICE guidance 
on the use of etanercept and efalizumab indicates 
that approximately 2% of the UK population 
have psoriasis.2 Defining what constitutes mild, 
moderate and severe psoriasis is also problematic 
as a number of different criteria are available and 
differing approaches are taken. One of the main 
accepted systems for classifying the severity of 
psoriasis is the Psoriasis Area and Severity Index 
(PASI). The limitations of this measure have been 
well documented,3 but despite its shortcomings it 
is the measure used in most clinical trials. Body 
surface area (BSA) and the Dermatology Life 
Quality Index (DLQI) are also commonly used 
as systems for classifying the severity of psoriasis. 
The guidance for the use of biological therapies 
in psoriasis issued by NICE in July 20062 defines 
severe psoriasis as a PASI of ≥ 10 combined with 
a DLQI > 10. A 2005 review4 of the PASI alone 
(i.e. without DLQI or BSA) as an instrument in 
determining the severity of chronic plaque-type 
psoriasis defines severe psoriasis as a PASI > 12 
and moderate psoriasis as a PASI ranging from 7 
to 12. 
Scope of the ERG report
The ERG critically evaluated the evidence 
submission from Abbott Laboratories on the use 
of adalimumab for the treatment of moderate 
to severe plaque psoriasis. At the time of the 
evaluation adalimumab had not yet been licensed 
for this indication.
Adalimumab is a recombinant human 
immunoglobulin monoclonal antibody that binds 
to the proinflammatory cytokine tumour necrosis 
factor-alpha (TNF-α). Adalimumab neutralises 
the biological function of TNF-α by blocking its 
interaction with the p55 and p75 cell-surface TNF 
receptors.Health Technology Assessment 2009; Vol. 13: Suppl. 2
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The anticipated licensed indication for 
adalimumab is the treatment of moderate to severe 
chronic plaque psoriasis in adult patients who 
failed to respond to or who have a contraindication 
to or who are intolerant to other systemic therapy 
including ciclosporin, methotrexate or PUVA.
The outcomes stated in the manufacturer’s 
definition of the decision problem were measures 
of severity of psoriasis, remission rate, adverse 
effects of treatment and health-related quality of 
life.
Methods 
The ERG report comprised a critical review of the 
evidence for the clinical effectiveness and cost-
effectiveness of the technology based upon the 
manufacturer’s/sponsor’s submission to NICE as 
part of the STA process. 
The ERG checked the literature searches and 
applied the NICE critical appraisal checklist to 
the included studies and checked the quality of 
the manufacturer’s submission with the Centre 
for Reviews and Dissemination (CRD) quality 
assessment criteria for a systematic review. 
In addition, the ERG checked and provided 
commentary on the manufacturer’s model using 
standard checklists. A one-way sensitivity analysis, 
scenario analysis and a probabilistic sensitivity 
analysis (Figure 1) were undertaken by the ERG.
Results 
Summary of submitted 
clinical evidence
The main evidence on efficacy in the submission 
comes from three randomised controlled trials 
(RCTs) comparing adalimumab with placebo. 
One of these RCTs also compares adalimumab 
with methotrexate. One further RCT contributes 
evidence on efficacy and time to relapse. 
Additionally two extension studies and one 
ongoing open-label extension study were included. 
Other than the one RCT mentioned above, which 
included a methotrexate arm, no trials of potential 
comparator treatments were included.
A higher proportion of patients on 40 mg 
adalimumab every other week achieved an 
improvement on the PASI of at least 75% (PASI 
75) compared with placebo groups after either 
12 weeks (two trials) or 16 weeks (two trials) of 
treatment. There was also a statistically significant 
difference in favour of adalimumab for the 
proportion of patients achieving a PASI 50 (three 
trials) and a PASI 90 (four trials).
The manufacturer’s submission did not present 
a narrative or quantitative synthesis of the data 
from the four trials except in the mixed treatment 
comparison. The mixed treatment comparison 
result for treatment with 40 mg adalimumab every 
other week was a mean probability of achieving a 
PASI 75 response to treatment of 67% (2.5–97.5% 
credible interval of 57–74%), compared with 
a mean probability of achieving a PASI 75 of 
5% (2.5–97.5% credible interval of 4–6%) with 
supportive care. The mixed treatment comparison 
results for PASI 50 and PASI 90 were also in favour 
of adalimumab over supportive care. For each 
PASI outcome in the mixed treatment comparison 
the probability of a response was greater for 
infliximab 5 mg/kg/day than for adalimumab, 
but the probability of response with adalimumab 
was greater than the probability of response with 
etanercept, efalizumab and the non-biological 
systemic therapies. 
In terms of secondary outcomes there were 
statistically significant differences between 
adalimumab and placebo in Physician’s Global 
Assessment (PGA) score, DLQI, the EuroQoL 
quality of life questionnaire (EQ-5D) and the short-
form version 36 (SF-36) quality of life outcomes. 
The incidence of any adverse event was similar in 
the treatment and placebo arms, serious adverse 
events were comparable and discontinuations 
because of adverse events were low and comparable 
between groups.
Summary of submitted cost-
effectiveness evidence
The cost-effectiveness analysis estimates the mean 
length of time that an individual would respond 
to treatment, and the utility gains associated 
with this response. The model is based closely 
upon the model reported in the NICE appraisal 
of etanercept and efalizumab for psoriasis.2 The 
results are presented for adalimumab compared 
with other biological therapies, including 
intermittent etanercept, based upon utility values 
obtained from two clinical trials.
The model is generally internally consistent and 
appropriate to psoriasis in terms of structural 
assumptions. The cost-effectiveness analysis 
generally conforms to the NICE reference case, the 
scope and the decision problem.Adalimumab for the treatment of psoriasis 
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Treatment effectiveness is reported in terms 
of the numbers of patients achieving PASI 50, 
75 and 90 goals at the end of the trial period. 
Evidence was synthesised from a variety of trials 
for all therapies considered in the model using 
a mixed treatment comparison model. Patients 
who achieve improvements in PASI score were 
assigned an associated improvement in quality of 
life with higher responses associated with larger 
improvements in quality of life. 
The base-case incremental cost-effectiveness ratio 
(ICER) for adalimumab compared with supportive 
care for patients with severe psoriasis was £30,538 
per quality-adjusted life-year (QALY). Scenario 
analysis reported in the manufacturer’s submission 
shows that the model was most sensitive to the 
utility values used (with DLQI ≤ 10 having much 
higher cost-effectiveness ratios then DLQI > 10).
Commentary on 
the robustness of 
submitted evidence
Strengths
The manufacturer conducted a systematic search 
for clinical effectiveness and cost-effectiveness 
studies of adalimumab. It appears unlikely that 
the searches missed any additional trials that 
would have met the inclusion criteria. The four key 
adalimumab trials identified were of reasonable 
methodological quality and measured a range of 
outcomes that are as appropriate and clinically 
relevant as possible. Overall, the manufacturer’s 
submission presents an unbiased estimate of 
treatment efficacy for adalimumab based on the 
results of the placebo-controlled trials.
The economic model presented with the 
manufacturer’s submission used an appropriate 
approach for the disease area given the available 
data. The measure of utility gain was taken from 
two randomised clinical trials that directly linked 
changes in PASI score to changes in utility using 
the EQ-5D. 
Weaknesses
The processes undertaken by the manufacturer 
for screening references, data extraction and 
quality assessment of included studies were not 
well reported in the manufacturer’s submission. 
However, the manufacturer was able to provide 
details when requested.
The manufacturer did not undertake a systematic 
review of the comparator trials and reported very 
limited information on the comparator trials that 
were included in the mixed treatment comparison. 
The manufacturer’s submission provided very 
little in the way of a narrative synthesis of outcome 
data from the key trials and did not perform a 
meta-analysis. A mixed treatment comparison was 
conducted, but few methodological details were 
provided on this.
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The assumptions made to estimate the cost-
effectiveness of intermittent etanercept used 
inconsistent methodology for costs and benefits. 
The estimation of QALYs and costs generated were 
based upon different estimates of the length of 
time that individuals would spend on etanercept, 
with the estimate used for costs greater than that 
used for QALYs.
There were no clear data on the amount of 
inpatient care required under supportive care.
A fourth infusion for infliximab was included in the 
trial period at 14 weeks. This would last for the first 
8 weeks of the treatment period and hence is most 
appropriately included in the treatment period 
costs. The clinical expert consulted believed that 
generally in clinical practice the fourth infusion 
would be given only after the individual’s response 
category was assessed. 
Conclusions 
Areas of uncertainty
As a standard meta-analysis was not conducted the 
overall treatment effect of adalimumab achieved 
across the trials is unknown. A meta-analysis might 
also have identified whether there is heterogeneity 
across the trials. If heterogeneity was found to 
be present the appropriateness of conducting a 
mixed treatment comparison would need to be 
reconsidered.
The limited descriptions of both the comparator 
trials included in the mixed treatment comparison 
and the methodological assumptions underlying 
the mixed treatment comparison make it difficult 
for the ERG to critique the model outputs. 
The extent to which the trial populations of the 
included adalimumab trials match the population 
specified in the decision problem, in terms of 
previous treatment with systemic therapy, is 
uncertain.
A regression model was used to relate changes in 
PASI score to EQ-5D data. However, few details 
were given of this model and so the ERG could 
not be sure of the appropriateness of the approach 
taken. 
Uncertainty exists as to the correct way to model 
key alternatives to adalimumab, particularly 
intermittent etanercept. It is unclear how widely 
intermittent etanercept is used in clinical practice 
and the degree to which costs are avoided with 
intermittent therapy. It is also unclear as to how 
much utility is lost because of psoriasis flare-ups. 
There appears to be a paucity of data regarding 
the need for inpatient stays in psoriasis patients. 
The assumption is that individuals who are not 
responders to treatment receive 21 days per 
year and those who are on treatment receive no 
inpatient stays. The model is sensitive to changes 
in the length of supportive care inpatient stay. 
Key issues 
The majority of the trials of adalimumab efficacy 
presented in the manufacturer’s submission were 
placebo-controlled trials. Only one head-to-
head RCT was included that directly compared 
adalimumab with methotrexate. No studies were 
identified that directly compared adalimumab 
with the other possible comparators listed in the 
scope. The manufacturer carried out an indirect 
comparison, but because of the limited information 
presented on the included comparison trials and 
the methodological assumptions the ERG have 
reservations about this.
The precise definition of the severity of the 
psoriasis patients included in the model is unclear. 
A clear specification of this and a tailoring of the 
effectiveness, quality of life and cost data, to reflect 
specific severities, would improve the applicability 
of the model.
There is a need for better data relating to the need 
for inpatient stays for non-responders with various 
severities of disease. 
The assumptions made in estimating the values 
for key parameters used for the comparators 
are important in determining the relative cost-
effectiveness of adalimumab compared with other 
biological treatments, particularly the costing 
assumptions made for intermittent etanercept. 
Summary of NICE guidance 
issued as a result of the STA 
NICE issued an Appraisal Consultation Document 
in January 2008 which states that:
1.1  Adalimumab is recommended as a treatment 
option for adults with plaque psoriasis in whom 
anti-tumour necrosis factor (TNF) treatment is 
being considered and when the following criteria 
are both met.Adalimumab for the treatment of psoriasis 
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  – The disease is severe as defined by a total 
Psoriasis Area Severity Index (PASI) of 10 or 
more and a Dermatology Life Quality Index 
(DLQI) of more than 10.
  – The psoriasis has not responded to standard 
systemic therapies including ciclosporin, 
methotrexate and PUVA (psoralen and long-
wave ultraviolet radiation); or the person is 
intolerant to, or has a contraindication to, 
these treatments.
1.2  It is recommended that adalimumab is 
discontinued in people whose psoriasis has not 
responded adequately at 12 weeks. An adequate 
response is defined as either:
  – a 75% reduction in the PASI score (PASI 75) 
from when treatment started, or
  – a 50% reduction in the PASI score (PASI 50) 
and a five-point reduction in DLQI from start 
of treatment. 
1.3  It is recommended that, when using the DLQI, 
healthcare professionals take care to ensure that a 
person’s disabilities (such as physical impairments) 
and linguistic or other communication difficulties 
are taken into account when reaching conclusions 
on the severity of plaque psoriasis. In such cases, 
healthcare professionals should ensure that their 
use of the DLQI continues to be a sufficiently 
accurate measure. The same approach should 
apply in the context of a decision about whether 
to continue the use of the drug in accordance with 
section 1.2.
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Abstract
This paper presents a summary of the evidence 
review group (ERG) report into the clinical 
effectiveness and cost-effectiveness of dabigatran 
etexilate (DBG) for the prevention of venous 
thromboembolism (VTE) in patients undergoing 
elective hip and knee surgery based upon a 
review of the manufacturer’s submission to the 
NICE as part of the single technology appraisal 
(STA) process. The submission’s evidence came 
from three reasonable-quality trials comparing 
DBG with enoxaparin, and a comparison of 
DBG with fondaparinux based on the relative 
efficacy and safety as derived from a mixed 
treatment comparison (MTC) meta-analysis. DBG 
(220 mg and 150 mg once daily) is not inferior to 
enoxaparin (40 mg once daily and 30 mg twice 
daily) in terms of major VTE or VTE-related events 
(secondary outcome). Meta-analysis shows that 
220 mg DBG is not inferior to enoxaparin (40 mg 
once daily or 30 mg twice daily) in reducing total 
VTE and all-cause mortality (primary outcome) 
in total hip or knee replacement, whereas there 
is uncertainty around the clinical effectiveness 
of 150 mg DBG for this outcome. In the MTC 
analysis DBG compared favourably with the other 
interventions, with the exception of extended 
enoxaparin and fondaparinux. The adverse event 
profile was not significantly different in those 
receiving DBG and those receiving enoxaparin. 
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The submitted two-phase economic model 
compares DBG with enoxaparin and fondaparinux 
in total hip and knee replacement. The model 
structure is appropriate and the model assumptions 
are reasonable. The health states, costs, utilities 
and recurrence rates used are considered to be 
appropriate for the required analysis. The model 
estimated that at the licensed dose of 220 mg once 
daily DBG dominates enoxaparin in both total 
hip replacement and total knee replacement and 
that at the lower dose of 150 mg once daily DBG 
dominates enoxaparin in total hip replacement 
and enoxaparin dominates DBG in total knee 
replacement. DBG is less cost-effective than 
fondaparinux in total hip replacement at both 
doses; the cost per quality-adjusted life-year of 
fondaparinux versus DBG is £11,111 and £6857 
for the higher and lower doses of DBG respectively. 
In total knee replacement, both DBG doses are 
dominated by fondaparinux. For DBG versus all 
comparators in all cases the cost-effectiveness 
results are based on small incremental cost and 
health benefits. Weaknesses of the submitted 
evidence include that methods used for screening 
studies, data extraction and applying quality 
assessment criteria to included studies, as well as 
key details of trials included in the MTC, were 
not adequately described. In addition, some 
input parameters into the modelling process are 
incorrect. The ERG was unable to correct all of 
these mistakes and the impact on the model results 
is therefore unknown. The National Institute for 
Health and Clinical Excellence guidance issued as a 
result of the STA states that DBG is recommended 
as an option for the primary prevention of VTE 
events in adults who have undergone elective total 
hip or knee replacement surgery.
Introduction 
The National Institute for Health and Clinical 
Excellence (NICE) is an independent organisation 
within the NHS that is responsible for providing 
national guidance on the treatment and care of 
people using the NHS in England and Wales. 
One of the responsibilities of NICE is to provide 
guidance to the NHS on the use of selected new 
and established health technologies, based on an 
appraisal of those technologies.
NICE’s single technology appraisal (STA) process 
is specifically designed for the appraisal of a single 
product, device or other technology, with a single 
indication, for which most of the relevant evidence 
lies with one manufacturer or sponsor.1 Typically, 
it is used for new pharmaceutical products close 
to launch. The principal evidence for an STA is 
derived from a submission by the manufacturer/
sponsor of the technology. In addition, a report 
reviewing the evidence submission is submitted 
by the evidence review group (ERG), an external 
organisation independent of NICE. This paper 
presents a summary of the ERG report for the STA 
of dabigatran etexilate for the prevention of venous 
thromboembolism in patients undergoing elective 
hip and knee surgery.2
Description of the 
underlying health problem
Venous thromboembolism (VTE) is the formation 
of a blood clot (thrombus) in a vein, which 
may dislodge from its site of origin to cause an 
embolism. Most thrombi occur in the deep veins of 
the legs; this is called deep vein thrombosis (DVT). 
Dislodged thrombi may travel to the lungs; this 
is called a pulmonary embolism (PE) and can be 
fatal. Thrombi can also cause long-term morbidity 
due to venous insufficiency and post-thrombotic 
syndrome, potentially leading to venous ulceration.
Recurrence of DVT is common. Studies have shown 
that up to 30% of patients who have experienced 
an acute DVT will experience one or more 
recurrences over the following 10–15 years.3–5
Total hip or knee replacement surgery is a 
strong risk factor for VTE. In the absence of 
thromboprophylaxis the risk of developing a DVT 
after a primary total hip replacement and after a 
primary total knee replacement is 50% and 60% 
respectively.6
Mortality due to VTE is significant. Long-term 
follow-up of patients who have experienced an 
episode of VTE (usually acute DVT) has shown that 
there is a high mortality rate over the subsequent 
10–15 years.3,5,7,8
PE has a high mortality rate with 13% proving fatal 
in elderly patients 1 month after onset9 and 17.5% 
within 3 months.10
The National Joint Registry for England and Wales 
recorded 61,456 hip replacement procedures, of 
which 10% were revisions or reoperations, and 
60,986 knee replacement procedures, of which 8% 
were revisions or reoperations, undertaken between 
1 January and 31 December 2006.11Health Technology Assessment 2009; Vol. 13: Suppl. 2
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Scope of the ERG report
The objective of the appraisal is to evaluate the 
clinical effectiveness and cost-effectiveness of 
dabigatran etexilate (DBG) within its licensed 
indication for the prevention of VTE after elective 
hip or knee replacement surgery in adults. The 
comparators are enoxaparin (a low-molecular-
weight heparin) and fondaparinux.
In total hip replacement, the recommended 
standard dose of DBG is 110 mg within 1–4 hours 
of surgery, continuing with 220 mg daily thereafter 
for a total of 28–35 days. In total knee replacement, 
the recommended standard dose is 110 mg within 
1–4 hours of surgery, continuing with 220 mg daily 
thereafter for a total of 10 days. A reduced dose 
of 150 mg once a day is recommended for special 
populations: those aged 75 years and older, those 
with moderate renal impairment and those taking 
amiodarone. 
The outcomes measured are mortality, incidence 
of DVT, incidence of PE, post DVT complications 
including post-thrombotic syndrome, length of 
hospital stay, health-related quality of life and 
adverse effects of treatment including bleeding 
events (minor and major). 
The comparison with enoxaparin is based on the 
evidence from two pivotal head-to-head DBG 
phase III clinical trials: RE-NOVATE12 in a total 
hip replacement population and RE-MODEL13 
in a total knee replacement population. There 
are no head-to-head trials comparing DBG with 
fondaparinux. This comparison is based on the 
relative efficacy and safety as derived from a mixed 
treatment comparison (MTC) meta-analysis.
The economic evaluation presented a cost–utility 
analysis with cost-effectiveness expressed in terms 
of incremental cost per quality-adjusted life-years 
(QALYs). Given the potential chronic nature of 
some complications arising from VTE, the time 
horizon of the model was lifetime. Costs were 
considered from an NHS and personal social 
services perspective.
Methods 
The ERG report comprised a critical review of the 
evidence for the clinical effectiveness and cost-
effectiveness of the technology based upon the 
manufacturer’s/sponsor’s submission to NICE as 
part of the STA process.
The only additional work undertaken by the ERG 
was a series of meta-analyses on the primary safety 
outcomes. There was no difference between DBG 
and enoxaparin in any of these outcomes.
The ERG requested the manufacturers to repeat 
the cost-effectiveness analysis with the inclusion 
of the RE-MOBILIZE study,14 a second trial in a 
total knee replacement population. The inclusion 
of the RE-MOBILIZE study reverses the results, 
from DBG dominating to DBG being dominated 
for both dosages. However, the manufacturers 
do not believe that the RE-MOBILIZE study is 
generalisable to the England and Wales setting. It 
is their opinion that these analyses are therefore 
inappropriate for this submission. The ERG’s 
clinical advisors agree with this opinion.
Results 
Summary of submitted 
clinical evidence
The main evidence in the submission is derived 
from three head-to-head, phase III, multi-arm, 
randomised, double-blind, controlled, non-
inferiority trials (RE-NOVATE, RE-MODEL 
and RE-MOBILIZE). These trials compared the 
efficacy and safety of DBG at doses of 220 mg and 
150 mg once daily with that of enoxaparin [40 mg 
once daily in RE-NOVATE and RE-MODEL, 
30 mg twice daily in RE-MOBILIZE] in patients 
undergoing total knee replacement (RE-MODEL 
and RE-MOBILIZE) or total hip replacement (RE-
NOVATE). Follow-up was 12–14 weeks. 
DBG (at both 220 mg once daily and 150 mg once 
daily) does not appear to be inferior to enoxaparin 
(40 mg once daily and 30 mg twice daily) in terms 
of the secondary efficacy outcome of major VTE or 
VTE-related events.
The meta-analysis of the primary efficacy outcome 
across all three trials, and across combinations of 
these trials, appears to show that the intervention 
DBG at a dose of 220 mg once daily was not 
inferior to the comparator enoxaparin (at either 
40 mg once daily or 30 mg twice daily) in reducing 
levels of total VTE and all-cause mortality among 
patients undergoing total hip replacement and 
total knee replacement. 
Evidence from post hoc subgroup analyses of the 
included trials indicates that the 150-mg once daily 
dose may be less effective in terms of incidence of 
total VTE and all-cause mortality than the 220-mg Dabigatran etexilate for the prevention of venous thromboembolism
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once daily dose in the special populations indicated 
for this lower dose and for whom the lower dose 
is specifically licensed. Safety outcomes were not 
reported for these subgroups.
The meta-analysis of the RE-MODEL and RE-
NOVATE trials appears to show that the 150-mg 
once daily dose of DBG is not inferior to the 
comparator enoxaparin (at either 40 mg once daily 
or 30 mg twice daily) in reducing levels of total VTE 
and all-cause mortality among patients undergoing 
total hip replacement and total knee replacement.
The meta-analyses of the two total knee 
replacement trials combined (RE-MODEL and RE-
MOBILIZE) and the three total knee replacement 
and total hip replacement trials combined (RE-
NOVATE, RE-MODEL and RE-MOBILIZE) appear 
to show that the 150-mg once daily dose of DBG 
is inferior to the comparator enoxaparin (at both 
40 mg once daily and 30 mg twice daily) in reducing 
levels of total VTE and all-cause mortality among 
patients undergoing total hip replacement and 
total knee replacement.
An MTC analysis compared the results of these 
trials of DBG with results for all other available 
interventions for patients undergoing surgery and 
at risk of DVT and found that DBG compared 
favourably with the other interventions, with 
the exception of extended enoxaparin and 
fondaparinux, which appear to be relatively 
more effective (level of statistical significance of 
difference not reported).
The adverse event profile was not significantly 
different in those receiving DBG compared with 
those receiving enoxaparin. The primary safety 
end point was major bleeding. Clinically relevant 
bleeding, any bleeding and liver function were also 
measured (secondary end points).
Summary of submitted cost-
effectiveness evidence
The model developed by Boehringer Ingelheim 
has an acute phase that starts at the time of surgery 
and ends at 10 weeks post surgery and a chronic 
phase with a lifetime horizon. The model compares 
DBG with enoxaparin and fondaparinux in both 
total hip replacement and total knee replacement. 
The acute phase model is a decision tree which 
predicts the health states that patients will be in at 
10 weeks based on evidence from phase III trials of 
DBG compared with enoxaparin and from an MTC 
of DBG compared with fondaparinux. At 10 weeks 
patients enter a chronic phase Markov model in 
the same health state in which they terminated the 
decision tree model. No further treatment effect 
is applied in the chronic phase model. Transition 
between states in the chronic phase model is 
dependent on VTE recurrence rates obtained from 
the literature. 
The health states, costs, utilities and recurrence 
rates used within the model are considered to be 
appropriate for the required analysis.
The Boehringer Ingelheim model estimated that:
•	 at the licensed dose of 220 mg once daily 
DBG dominates enoxaparin in both total hip 
replacement and total knee replacement
•	 at the lower dose of 150 mg once daily DBG 
dominates enoxaparin in total hip replacement 
and enoxaparin dominates DBG in total knee 
replacement
•	 DBG is less cost-effective than fondaparinux 
in total hip replacement at both doses of DBG. 
The cost/QALY of fondaparinux versus DBG is 
£11,111 and £6857, respectively, for the higher 
and lower doses of DBG.
•	 In total knee replacement, both DBG doses are 
dominated by fondaparinux.
Table 1 presents a summary of the cost-effectiveness 
results. For DBG versus all comparators it should 
be noted that in all cases the cost-effectiveness 
results are based on small incremental cost and 
health benefits.
Commentary on 
the robustness of 
submitted evidence
Strengths
The manufacturer conducted a limited, but 
systematic search for clinical and cost-effectiveness 
studies of DBG for the prevention of VTE in 
patients undergoing total knee replacement and 
total hip replacement. It appears unlikely that 
any additional trials would have met the inclusion 
criteria had the search been widened to include 
more free-text terms or to include other databases. 
The three identified trials, which represent the 
main clinical efficacy evidence, were of reasonable 
methodological quality, with some limitations, 
and measured a range of outcomes that were 
appropriate and clinically relevant. Health Technology Assessment 2009; Vol. 13: Suppl. 2
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TABLE 1  Summary of deterministic and probabilistic sensitivity analysis results 
Probability cost-effective at 
threshold:
Deterministic £20,000/QALY £30,000/QALY
DBG compared with enoxaparin in THR patients
DBG 220 mg
Incremental cost –£99 99% 98%
Incremental QALYs 0.010
ICER DBG dominant
DBG 150 mg
Incremental cost –£83 76% 71%
Incremental QALYs 0.001
ICER DBG dominant
DBG compared with enoxaparin in TKR patients
DBG 220 mg
Incremental cost –£18 82% 82%
Incremental QALYs 0.011
ICER DBG dominant
DBG 150 mg
Incremental cost £20 38% 39%
Incremental QALYs –0.002
ICER DBG dominated
DBG compared with fondaparinux in THR patients
DBG 220mg
Incremental cost –£200 40% 35%
Incremental QALYs –0.018
ICER £11,111a
DBG 150mg
Incremental cost –£192 32% 27%
Incremental QALYs –0.028
ICER £6857a
DBG compared with fondaparinux in TKR patients
DBG 220 mg
Incremental cost £16 0% 0%
Incremental QALYs –0.016
ICER DBG dominated
DBG 150 mg
Incremental cost £25 0% 0%
Incremental QALYs –0.019
ICER DBG dominated
DBG, dabigatran etexilate; ICER, incremental cost-effectiveness ratio; QALY(s), quality-adjusted life-year(s); THR, total hip 
replacement; TKR, total knee replacement.
a  Note that this ICER is in the ‘south/west’ quadrant of the cost-effectiveness plane.Dabigatran etexilate for the prevention of venous thromboembolism
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The meta-analyses demonstrated the non-
inferiority of DBG 220 mg once daily versus 
enoxaparin in terms of the efficacy and safety end 
points, and acknowledged the apparent inferiority 
of the 150-mg once daily dose in terms of the 
primary efficacy outcome.
An MTC analysis compared DBG with all other 
available interventions for patients undergoing 
surgery and at risk of DVT and found that DBG 
compared favourably with the other interventions, 
with the exception of extended low-molecular-
weight heparins and fondaparinux, which appear 
to be more effective.
The model structure is appropriate and allows 
sensitivity analysis to be carried out easily.
The model assumptions are reasonable.
The univariate sensitivity analysis is extensive and 
is performed on appropriate parameters.
The probabilistic sensitivity analysis is performed 
correctly.
Weaknesses
The processes undertaken by the manufacturer for 
screening studies, data extraction and applying 
quality assessment criteria to included studies were 
not made explicitly clear in the submission. These 
factors limit the robustness of the systematic review. 
Quality assessment of the included studies should 
have been undertaken using a checklist appropriate 
to the types of study included (non-inferiority 
randomised trials).
One of the trials used in the clinical effectiveness 
section is published only as an abstract (RE-
MOBILIZE); much of the key data employed are 
unpublished.
A simple pooled analysis of the patient level data 
from the two pivotal trials, as well as all three 
head-to-head trials, was reported. However, the 
methods used for this data pooling were not 
described; the statistical approach for combining 
the data appears to be inappropriate as it fails to 
preserve randomisation and introduces bias and 
confounding. The resulting pooled data should 
therefore be treated with caution.
Elements of the MTC reported in the 
manufacturer’s submission are reproduced from 
documents produced by organisations other 
than the manufacturer, rather than specifically 
in response to the scope. The key details of trials 
included in the MTC, and issues relating to 
heterogeneity of trials, are neither reported nor 
discussed. The resulting MTC should therefore be 
treated with caution.
The economic results for DBG compared with 
enoxaparin in total hip replacement and total 
knee replacement both rely on one trial each. 
These trials indicate that DBG is not inferior 
to enoxaparin. The small numerical difference 
seen in these trials is reproduced in the model in 
terms of both incremental costs and incremental 
health benefits (see Table 1). A small change in 
the direction of the trial results could significantly 
change the cost-effectiveness conclusions.
The economic results for DBG versus fondaparinux 
in total hip replacement are based on one study 
for which the manufacturer appears to have used 
an incorrect relative risk estimate. However, the 
difference is small and the impact on the results is 
likely to be small.
VTE recurrence rates, post-thrombotic syndrome 
rates and quality of life utilities used in the model 
are based on a literature review limited to economic 
studies. It is therefore possible that non-economic 
studies reporting these data in sources such as 
MEDLINE have not been identified.
Some input parameters into the modelling process 
are incorrect. These include using the underlying 
risk of DVT instead of the underlying risk of VTE 
for the comparison of DBG with fondaparinux, 
wrongly estimating the recurrence rates for VTE, 
wrongly estimating the probability of PE being 
severe, not including intensive care unit costs in PE 
post discharge and including the cost of informal 
care when it should be excluded. The ERG was 
unable to correct all of these mistakes and the 
impact on the model results is therefore unknown.
Conclusions 
Key issues 
The external validity of the evidence is limited. 
Only a single randomised controlled trial 
(RCT) using a comparator and dose applied in 
England and Wales has been conducted on each 
of the relevant total hip replacement and total 
knee replacement populations. The addition of 
evidence from any future RCTs may alter the 
results regarding the non-inferiority of DBG. Small 
changes in key parameters could markedly alter Health Technology Assessment 2009; Vol. 13: Suppl. 2
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the conclusions with respect to cost and clinical 
effectiveness.
The results of the RE-MOBILIZE total knee 
replacement trial indicate that both the 220-
mg once daily and the 150-mg once daily dose 
of DBG are inferior to enoxaparin in terms of 
the primary efficacy outcome of total VTE and 
all-cause mortality. When the pivotal trials (RE-
MODEL and RE-NOVATE) are combined with this 
trial in a meta-analysis the 150-mg once daily dose 
of DBG is found to be inferior to enoxaparin in 
terms of the primary efficacy outcome. The 150-
mg once daily dose may therefore not be suitable 
for use in the special populations indicated. Post 
hoc subgroup analyses for total VTE and all-cause 
mortality conducted on the special populations 
indicated also suggest that this dose may be less 
effective than the 220-mg once daily dose in terms 
of the primary efficacy outcome.
The economic results for DBG compared with 
enoxaparin in total hip replacement and total 
knee replacement both rely on one trial each. 
These trials indicate that DBG is not inferior to 
enoxaparin. Although at the licensed dose of 
220 mg once daily DBG dominates enoxaparin, 
a small change in the direction of the trial results 
could significantly alter the cost-effectiveness 
conclusions.
The cost-effectiveness analysis based on a meta-
analysis of the RE-MODEL plus the RE-MOBILIZE 
trials reverses the direction of the results, that is, 
DBG is now dominated by enoxaparin for both 
doses. However, it is the manufacturer’s opinion 
that the RE-MOBILIZE study is not generalisable 
to the England and Wales setting. This is also the 
opinion of the clinical advisors to the ERG.
Areas of uncertainty
There is uncertainty around the clinical 
effectiveness and cost-effectiveness of DBG 
compared with other relevant treatments included 
in the scope, especially fondaparinux and standard 
and extended low-molecular-weight heparins other 
than enoxaparin, especially with respect to the 150-
mg once daily dose. The 150-mg once daily dose 
may be less effective than the 220-mg once daily 
dose for the special populations for whom this 
lower dose is licensed.
The economic results for DBG compared with 
enoxaparin in total hip replacement and total 
knee replacement both rely on one trial each. 
The small numerical difference seen in these 
trials is reproduced in the model in terms of both 
incremental costs and incremental health benefits. 
The conclusions of the cost-effectiveness analysis 
could be significantly changed with only a small 
change in the direction of the trial results.
Summary of NICE guidance 
issued as a result of the STA 
At the time of writing, the final appraisal 
determination issued by NICE on 21 July 2008 
states that:
Dabigatran etexilate, within its marketing 
authorisation, is recommended as an option for 
the primary prevention of venous thromboembolic 
events in adults who have undergone elective total 
hip replacement surgery or elective total knee 
replacement surgery.
Key references
1.  National Institute for Health and Clinical 
Excellence. Guide to the single technology (STA) process. 
19 September 2006. URL: www.nice.org.uk/page.
aspx?o=STAprocessguide.
2.  Holmes M, Carroll C, Papaioannou D. Dabigatran 
etexilate for the prevention of venous thromboembolism 
in patients undergoing elective hip and knee surgery: a 
single technology appraisal. NICE Guidance 2008; 
157.
3.  Bergqvist D, Jendteg S, Johansen L, Persson U, 
Odegaard K. Cost of long-term complications of 
deep venous thrombosis of the lower extremities: an 
analysis of a defined patient population in Sweden. 
Ann Intern Med 1997;126:454–7.
4.  Janssen MC, Haenen JH, van Asten WN, 
Wollersheim H, Heijstraten FM, de Rooij MJ, et 
al. Clinical and haemodynamic sequelae of deep 
venous thrombosis: retrospective evaluation after 
7–13 years. Clin Sci (Lond) 1997;93:7–12.
5.  Schulman S, Lindmarker P, Holmstrom M, Larfars 
G, Carlsson A, Nicol P, et al. Post-thrombotic 
syndrome, recurrence, and death 10 years after the 
first episode of venous thromboembolism treated 
with warfarin for 6 weeks or 6 months. J Thromb 
Haemost 2006;4:734–42.
6.  Faroug R, Konnuru S, Min S, Hussain F, Ampat G. 
Venous thromboembolism prevention post neck 
of femur fractures – does it make a difference? 
Thrombosis J 2008;6:8
7.  Eichlisberger R, Widmer MT, Frauchiger B, Widmer 
LK, Jager K. [The incidence of post-thrombotic Dabigatran etexilate for the prevention of venous thromboembolism
62
syndrome] [German]. Wien Med Wochenschr 
1994;144:192–5.
8.  Murray DW, Britton AR, Bulstrode CJ. 
Thromboprophylaxis and death after total hip 
replacement. J Bone Joint Surg Br 1996;78:863–70.
9.  Siddique RM, Siddique MI, Connors AF, Jr, 
Rimm AA. Thirty-day case-fatality rates for 
pulmonary embolism in the elderly. Arch Intern Med 
1996;156:2343–7.
10.  Goldhaber SZ, Visani L, De Rosa M. Acute 
pulmonary embolism: clinical outcomes in the 
International Cooperative Pulmonary Embolism 
Registry (ICOPER). Lancet 1999;353:1386–9.
11.  National Joint Registry for England and Wales 
4th Annual Report. URL: www.rcseng.ac.uk/
surgical_research_units/docs/National%20Joint%20
Registry%20Report%202007.pdf.
12.  Eriksson BI, Dahl OE, Rosencher N, Kurth AA, 
van Dijk CN, Frostick SP, et al; RE-NOVATE Study 
Group. Dabigatran etexilate versus enoxaparin for 
prevention of venous thromboembolism after total 
hip replacement: a randomised, double-blind, non-
inferiority trial. Lancet 2007;370:949–56.
13.  Eriksson BI, Dahl OE, Rosencher N, Kurth AA, van 
Dijk CN, Frostick SP, et al. Oral dabigatran etexilate 
vs. subcutaneous enoxaparin for the prevention 
of venous thromboembolism after total knee 
replacement: the RE-MODEL randomized trial. J 
Thromb Haemost 2007;5:2178–85.
14.  Friedman RJ, Caprini JA, Comp PC, Davidson 
BL, Francis CW, Ginsberg J, et al. Dabigatran 
etexilate versus enoxaparin in preventing venous 
thromboembolism following total knee arthroplasty. 
J Thromb Haemost 2007;5(Suppl. 2):W-051.Health Technology Assessment 2009; Vol. 13: Suppl. 2
© 2009 Queen’s Printer and Controller of HMSO. All rights reserved.
63
Romiplostim for the treatment of chronic 
immune or idiopathic thrombocytopenic purpura: 
a single technology appraisal 
G Mowatt,* C Boachie, M Crowther, C Fraser, R Hernández, 
X Jia and L Ternent
Aberdeen Health Technology Assessment Group, University of Aberdeen, UK
*Corresponding author
Declared competing interests of authors: none
Abstract
This paper presents a summary of the evidence 
review group (ERG) report into the clinical and 
cost-effectiveness of romiplostim for the treatment 
of adults with chronic immune or idiopathic 
thrombocytopenic purpura (ITP) based upon 
a review of the manufacturer’s submission to 
the National Institute for Health and Clinical 
Excellence (NICE) as part of the single technology 
appraisal (STA) process. The submission’s 
evidence came from two relatively high-quality 
randomised controlled trials (RCTs). The ERG 
found no evidence that any important data were 
missed or that data extraction was inaccurate. 
In both RCTs more patients in the romiplostim 
than in the placebo group achieved a durable 
platelet response [non-splenectomised patients: 
romiplostim 25/41 (61%), placebo 1/21 (5%), odds 
ratio (OR) 24.45, 95% confidence interval (CI) 3.34 
to 179.18; splenectomised patients: romiplostim 
16/42 (38%), placebo 0/21 (0%), OR 8.5 (95% CI 
1.15 to 372)] and an overall platelet response  
[non-splenectomised patients: romiplostim 36/41 
(88%), placebo 3/21 (14%), OR 34.74, 95% CI 7.77 
to 155.38; splenectomised patients: romiplostim 
33/42 (79%), placebo 0/21 (0%), OR 16.6 (95% CI 
2.37 to 706]. The difference in mean period with 
a platelet response was 13.9 weeks (95% CI 10.5 
to 17.4) in favour of romiplostim in the RCT of 
non-splectomised patients and 12.1 weeks (95% 
CI 8.7 to 15.6) in favour of romiplostim in the 
RCT of splectomised patients. The manufacturer’s 
economic model evaluated the cost-effectiveness 
of romiplostim compared with standard care. The 
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ERG had concerns about the way the decision 
problem was addressed in the economic model 
and about the non-adjustment of findings for 
confounding factors. In non-splenectomised 
patients, using romiplostim as a first option 
treatment, the base-case incremental cost-
effectiveness ratio (ICER) was £14,840 per quality-
adjusted life-year (QALY). In splenectomised 
patients the ICER was £14,655 per QALY. 
Additional sensitivity analyses performed by the 
ERG identified two issues of importance: whether 
individuals entered the model on watch and 
rescue or on active therapy in the comparator arm 
(ICER £21,674 per QALY for non-splenectomised 
patients, £29,771 per QALY for splenectomised 
patients); whether it was assumed that any unused 
medicine would be wasted. Combining all of the 
separate sensitivity analyses, and assuming that 
watch and rescue was not the first-line treatment, 
increased the ICERs further (non-splenectomised 
£37,290 per QALY; splenectomised £131,017 
per QALY). In conclusion, the manufacturer’s 
submission and additional work conducted by 
the ERG suggest that romiplostim has short-term 
efficacy for the treatment of ITP, but there is no 
robust evidence on long-term effectiveness or 
cost-effectiveness of romiplostim compared with 
relevant comparators.
Introduction 
The National Institute for Health and Clinical 
Excellence (NICE) is an independent organisation 
within the NHS that is responsible for providing 
national guidance on the treatment and care of 
people using the NHS in England and Wales. 
One of the responsibilities of NICE is to provide 
guidance to the NHS on the use of selected new 
and established health technologies, based on an 
appraisal of those technologies.
NICE’s single technology appraisal (STA) process 
is specifically designed for the appraisal of a single 
product, device or other technology, with a single 
indication, for which most of the relevant evidence 
lies with one manufacturer or sponsor.1 Typically, 
it is used for new pharmaceutical products close 
to launch. The principal evidence for an STA is 
derived from a submission by the manufacturer/
sponsor of the technology. In addition, a report 
reviewing the evidence submission is submitted 
by the evidence review group (ERG), an external 
organisation independent of NICE. This paper 
presents a summary of the ERG report for the 
STA of romiplostim for the treatment of chronic 
immune or idiopathic thrombocytopenic purpura 
(ITP).
Description of the 
underlying health problem
Immune thrombocytopenic purpura is a 
condition in which autoantibodies are formed 
against platelets. ITP may present as bleeding 
and/or bruising or may be asymptomatic and 
picked up on blood counts taken for other 
reasons. The incidence rates quoted for adult 
ITP in the UK/USA range from 1.132 to 6.63 
per 100,000 per year. Licensed treatments for 
ITP are steroids, intravenous immunoglobulin 
and anti-D immunoglobulin. Other treatments 
include splenectomy (a surgical treatment), 
cyclophosphamide, vinca alkaloids, danazol, 
azathioprine, ciclosporin, rituximab, 
mycophenolate mofetil, dapsone, alemtuzumab, 
autologous stem cell transplantation, interferon 
and combination chemotherapy. More recent novel 
treatments include the thrombopoietin analogues 
(romiplostim and eltrombopag), which appear to 
increase platelet production.
Scope of the ERG report
The manufacturer’s submission assessed the 
efficacy, safety and cost-effectiveness of romiplostim 
for the treatment of chronic ITP in adult patients 
with platelet counts of less than 30 × 109/l. Two 
subgroups were assessed: non-splenectomised 
patients with inadequate response to initial 
corticosteroid treatment, in whom splenectomy 
was medically contraindicated, and ITP patients 
refractory to splenectomy. The primary outcome 
was the incidence of durable response, defined 
as achieving at least six weekly platelet responses 
(platelets ≥ 50 × 109/l) during the last 8 weeks of 
treatment with no rescue medications administered 
at any time during the 24-week treatment period. 
The data used to assess the efficacy and safety of 
romiplostim came from two small randomised 
controlled trials (RCTs) by Kuter and colleagues4 
comparing romiplostim with placebo in (1) non-
splenectomised patients and (2) splenectomised 
patients. In addition, data were also reported for 
an ‘ITP safety set’ consisting of a number of other 
non-randomised phase II studies.
The manufacturer submitted an economic 
evaluation. The economic model was a cohort-type 
model constructed in Microsoft excel in which the 
two patient populations were modelled. The model 
evaluated the cost-effectiveness of romiplostim 
compared with standard care, defined by reference 
to international guidelines in the treatment of Health Technology Assessment 2009; Vol. 13: Suppl. 2
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ITP and the manufacturer’s own commissioned 
survey. In the model, patients initially enter a 
watch and rescue state or are treated first with 
romiplostim. The model was populated with a 
variety of observational data for the effectiveness 
of alternative treatments from a number of small 
studies. The RCT data on romiplostim were also 
treated as observational data within the economic 
model.
Romiplostim is designed to increase the production 
of platelets at a rate that outpaces their destruction 
by the immune system. The European Medicines 
Agency’s (EMEA) Committee for Medicinal 
Products for Human Use (CHMP) positive 
opinion for romiplostim (Nplate™, Amgen) stated 
that Nplate was indicated for adult chronic ITP 
splenectomised patients who were refractory to 
other treatments, and that Nplate could also be 
considered as second-line treatment for adult 
non-splenectomised patients in whom surgery was 
contraindicated.
Methods 
The ERG report comprised a critical review of the 
evidence for the clinical effectiveness and cost-
effectiveness of the technology based upon the 
manufacturer’s/sponsor’s submission to NICE as 
part of the STA process. 
Following submission of the manufacturer’s report 
the ERG:
•	 requested clarification from the manufacturer 
on a number of points, mainly relating to the 
clinical effectiveness and cost-effectiveness 
aspects of the submission
•	 assessed the clinical effectiveness part of the 
manufacturer’s submission for its quality as a 
systematic review using the questions in the 
Centre for Reviews and Dissemination (CRD) 
Report No. 45
•	 replicated the manufacturer’s MEDLINE 
search strategy with the inclusion of the term 
‘nplate.tw,rn’ and adapted the searches for the 
other databases using the appropriate subject 
heading terms
•	 undertook complementary searches for 
additional evidence on each comparator
•	 requested the manufacturer to rerun the 
economic model for a number of additional 
analyses, and
•	 performed additional sensitivity analyses on 
the economic model.
Results 
Summary of submitted 
clinical evidence
Evidence on the efficacy of romiplostim came from 
two RCTs by Kuter and colleagues with a 24-week 
follow-up.4 In the RCT of non-splenectomised 
patients, 25/41 (61%) patients in the romiplostim 
group and 1/21 (5%) in the placebo group achieved 
a durable platelet response [odds ratio (OR) 24.45, 
95% confidence interval (CI) 3.34 to 179.18]. An 
overall platelet response was achieved by 36/41 
(88%) patients in the romiplostim group and 3/21 
(14%) in the placebo group (OR 34.74, 95% CI 
7.77 to 155.38). The Kaplan–Meier estimated 
median time to the first platelet response was 2.0 
weeks and the mean period with a platelet response 
was 15.2 weeks for romiplostim and 1.3 weeks for 
placebo (difference 13.9 weeks, 95% CI 10.5 to 
17.4 weeks).
In the RCT of splenectomised patients, 16/42 
(38%) patients in the romiplostim group and 0/21 
(0%) in the placebo group achieved a durable 
platelet response. The OR estimated by the ERG 
using an assumption of one event in the placebo 
group was 8.5 (95% CI 1.15 to 372). An overall 
platelet response was achieved by 33/42 (79%) 
patients in the romiplostim group and 0/21 (0%) in 
the placebo group. The OR estimated by the ERG 
using the same assumption above was 16.6 (95% CI 
2.37 to 706). The Kaplan–Meier estimated median 
time to the first platelet response was 3.0 weeks and 
the mean period with a platelet response was 12.3 
weeks for romiplostim and 0.2 weeks for placebo 
(difference 12.1 weeks, 95% CI 8.7 to 15.6 weeks).
The efficacy of 24-week administration of 
romiplostim was significantly better than that 
of placebo in the above outcomes and also in 
reduction of concurrent ITP therapy. Across 
both studies headache (29/84, 35%) was the 
most common adverse drug reaction amongst 
romiplostim patients, followed by arthralgia 
(22/84, 26%), dizziness (14/84, 17%) and insomnia 
(13/84, 15%). In the RCT of splenectomised 
patients three patients in the placebo group died, 
with causes of death pneumonia, pulmonary 
embolism and cerebral haemorrhage. In the RCT 
of non-splenectomised patients one patient in the 
romiplostim group died, the cause of death being 
an intracranial haemorrhage. 
The manufacturer used evidence from existing 
reviews and primary studies from complementary 
searches to report the efficacy and safety of Romiplostim for the treatment of chronic immune or idiopathic thrombocytopenic purpura
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comparator drugs. The majority of the efficacy and 
safety data came from non-randomised studies or 
case series. 
Summary of submitted cost-
effectiveness evidence
The manufacturer’s economic model evaluated the 
cost-effectiveness of romiplostim compared with 
standard care, defined by reference to international 
guidelines on the treatment of ITP and the 
manufacturer’s own commissioned survey. In the 
model, patients initially entered a watch and rescue 
state or were treated first with romiplostim. 
The results from the manufacturer’s revised base-
case analysis showed that, in non-splenectomised 
patients, using romiplostim as a first option 
treatment resulted in an incremental cost-
effectiveness ratio (ICER) of £14,840 per quality-
adjusted life-year (QALY). In splenectomised 
patients the ICER was £14,655 per QALY. 
Additional sensitivity analyses were performed 
by the ERG (Tables 1 and 2). The combined 
sensitivity analysis provided far larger changes in 
the ICER than were reflected in one-way sensitivity 
analysis. The two issues of most importance were 
(1) whether individuals entered the model on 
watch and rescue or on an active therapy in the 
comparator arm (ICER £21,674 per QALY for 
non-splenectomised patients, £29,771 per QALY 
for splenectomised patients) and (2) as vials of the 
drug came in a fixed size, whether it was assumed 
that any unused medicine would be wasted. 
Combining all of the separate sensitivity analyses, 
with the additional assumption that watch and 
rescue was not the first-line treatment, increased 
the ICERs further (non-splenectomised £37,290 
per QALY; splenectomised £131,017 per QALY).
Commentary on 
the robustness of 
submitted evidence
Overall the quality of the RCTs reporting 
romiplostim was relatively high and the ERG found 
no evidence that any data of consequence were 
missed in the reviews or that data extraction was 
inaccurate. The evidence base for both romiplostim 
and the comparator treatments was limited. 
Although the decision problem, description of 
alternatives and perspective were all well outlined 
TABLE 1  ERG’s exploratory sensitivity analyses (non-splenectomised patients)
Scenario
ICER (£ per QALY gained)
Watch and rescue is 
initial comparator 
intervention 
(as adopted by 
manufacturer)
Rituximab is initial 
comparator intervention 
(ERG analysis using 
manufacturer’s model)
Base case  14,633 21,674
1.  Use of EQ-5D data from RCTs 16,503 24,426
2.  Change in number of vials (from 0.93 to 1.0) 21,214 28,556
3.  Serious adverse events +50% 14,623 21,658
4.  Serious adverse events –50% 14,641 29,741
5.  Cost of bone marrow test included 14,663 21,706
6.  Cost of blood assessment included 19,230 36,131
7.  Reducing frequency of physician visits 14,669 21,701
8.  Combining 1 and 2 and 4–7 29,179 37,290
9.  Response rate for romiplostim (worst case for censoring) 16,258 57,593
10.  Response rate for romiplostim (best case for censoring) 14,152 18,776
11.  Combining 8 and 9 29,934 76,728
12.  Romiplostim effectiveness reduced to 0.25 of base case  16,354 165,129
13.  Romiplostim effectiveness reduced to 0.75 of base case  14,884 26,439
EQ-5D, EuroQol 5 dimensions questionnaire; ERG, evidence review group; ICER, incremental cost-effectiveness ratio; QALY, 
quality-adjusted life year; RCTs, randomised controlled trials.Health Technology Assessment 2009; Vol. 13: Suppl. 2
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in the submission, there were some concerns about 
the way that the decision problem was addressed in 
the economic model, which related to the structure 
of the model and whether patients entered 
the model on watch and rescue or on an active 
treatment. 
The ERG raised a number of concerns about the 
pre-model data analyses and the statistical and 
epidemiological techniques employed. These 
concerns related to the manufacturer not adjusting 
the findings for confounding factors (e.g. severity 
of ITP, age, number of previous treatments, 
concurrent treatments, and withdrawal rates), 
which might affect the reliability and size of the 
treatment effect. 
Conclusions 
Based on the manufacturer’s submission and 
the additional work conducted by the ERG the 
evidence available for romiplostim for both non-
splenectomised and splenectomised patient groups 
suggests that:
•	 romiplostim appears to be a safe treatment for 
ITP, although no long-term data exist
•	 romiplostim has short-term efficacy for the 
treatment of ITP
•	 there is no robust evidence on long-term 
efficacy of romiplostim
•	 there is no robust evidence on long-term 
effectiveness of romiplostim compared with 
relevant comparators
•	 there is no robust evidence on long-term cost-
effectiveness of romiplostim compared with 
relevant comparators.
Key issues for the decision-making process are:
•	 Will the use of romiplostim lead to wastage 
of the drug? Within the base-case industry 
submission it was assumed that there would 
be no wastage, but if there is then the cost-
effectiveness of romiplostim will be reduced.
•	 Is the appropriate comparison for romiplostim 
an active treatment rather than watch and 
rescue? If so then the use of romiplostim is far 
less likely to be considered cost-effective.
•	 Can the results of an international study be 
extrapolated to the UK population? There 
appeared to be differences between the study 
population and the average UK patient.
•	 Is it plausible that patients in the romiplostim 
trial who were censored were more likely to 
TABLE 2  ERG’s exploratory sensitivity analyses (splenectomised patients)
Scenario
ICER (£ per QALY gained)
Watch and rescue is 
initial comparator 
intervention 
(as adopted by 
manufacturer)
Rituximab is 
initial comparator 
intervention (ERG 
analysis using 
manufacturer’s model)
Base case 15,595 29,771
1.  Use of EQ-5D data from RCTs 17,580 33,558
2.  Change in number of vials (from 1.38 to 2.0) 91,406 109,802
3.  Serious adverse events +50% 15,580 21,687
4.  Serious adverse events –50% 15,608 29,796
5.  Cost of bone marrow test included 15,639 29,817
6.  Cost of blood assessment included 22,068 26,154
7.  Reducing frequency of physician visits 15,642 29,803
8.  Combining 1 and 2 and 4–7 110,352 131,017
9.  Response rate for romiplostim (worst case for censoring) 17,501 106,703
10.  Response rate for romiplostim (best case for censoring) 15,367 24,669
11.  Combining 8 and 9 106,515  233,106 
12.  Romiplostim effectiveness reduced to 0.25 of base case  17,245 446,204
13.  Romiplostim effectiveness reduced to 0.75 of base case  15,808 39,268
EQ-5D, EuroQol-5 dimensions questionnaire; ERG, evidence review group; ICER, incremental cost-effectiveness ratio; QALY, 
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cease to respond to romiplostim? If so then 
the use of romiplostim is far less likely to be 
considered cost-effective.
•	 What is the extent and direction of bias caused 
by the use of indirect comparisons of non-
comparative observational data? If the current 
data, as used in the manufacturer’s submission, 
overestimate the relative effectiveness of 
romiplostim then it is far less likely to be 
considered cost-effective.
Summary of NICE guidance 
issued as a result of the STA 
At the time of writing, the guidance had not been 
issued by NICE .
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Abstract
The submission’s evidence for the clinical 
effectiveness and cost-effectiveness of sunitinib for 
the treatment of gastrointestinal stromal tumours 
(GISTs) is based on a randomised controlled trial 
(RCT) comparing sunitinib with placebo for people 
with unresectable and/or metastatic GIST after 
failure of imatinib and with Eastern Cooperative 
Oncology Group (ECOG) progression status 0–1, 
and an ongoing, non-comparative cohort study of 
a similar population but with ECOG progression 
status 0–4. The searches are appropriate and 
include all relevant studies and the RCT is of 
high quality. In the RCT sunitinib arm overall 
survival was 73 median weeks [95% confidence 
interval (CI) 61 to 83] versus 75 median weeks 
(95% CI 68 to 84) for the cohort study. However, 
time to tumour progression in the cohort study 
was different from that in the RCT sunitinib arm 
[41 (95% CI 36 to 47) versus 29 (95% CI 22 to 41) 
median weeks respectively]. Median progression-
free survival with sunitinib was 24.6 weeks (95% CI 
12.1 to 28.4) versus 6.4 weeks (95% CI 4.4 to 10.0) 
on placebo (hazard ratio 0.333, 95% CI 0.238 to 
0.467, p < 0.001). The manufacturer used a three-
state Markov model to model the cost-effectiveness 
of sunitinib compared with best supportive care for 
GIST patients; the modelling approach and sources 
and justification of estimates are reasonable. The 
base-case incremental cost-effectiveness ratio 
(ICER) was £27,365 per quality-adjusted life-year 
(QALY) with the first cycle of sunitinib treatment 
not costed; when we included the cost of the 
first treatment cycle we estimated a base-case 
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ICER of £32,636 per QALY. Pfizer’s sensitivity 
analysis produced a range of ICERs from £15,536 
per QALY to £59,002 per QALY. Weaknesses of 
the manufacturer’s submission include that the 
evidence is based on only one published RCT; that 
84% of the RCT control population crossed over 
to the intervention group, giving rise to the use 
of unusual rank preserved structural failure time 
(RPSFT) analysis to correct for possible bias; and 
that a number of errors and omissions were made 
in the probabilistic sensitivity analysis, meaning 
that it is not possible to come to firm conclusions 
about the cost-effectiveness of sunitinib for GIST 
in this patient population. In conclusion, during 
the blinded phase of the RCT, overall survival was 
significantly longer in the sunitinib arm than in 
the placebo arm (hazard ratio 0.491, 95% CI 0.290 
to 0.831, p <0.007). However, intention-to-treat 
analysis of the entire study showed no statistically 
significant difference in overall survival for those 
who received sunitinib (73 weeks) versus those who 
received placebo (65 weeks) (hazard ratio 0.876, 
95% CI 0.679 to 1.129, p = 0.306). 
Introduction 
The National Institute for Health and Clincal 
Excellence (NICE) is an independent organisation 
within the NHS that is responsible for providing 
national guidance on the treatment and care of 
people using the NHS in England and Wales. 
One of responsibilities of NICE is to provide 
guidance to the NHS on the use of selected new 
and established health technologies, based on an 
appraisal of those technologies.
NICE’s single technology appraisal (STA) process 
is specifically designed for the appraisal of a single 
product, device or other technology, with a single 
indication, for which most of the relevant evidence 
lies with one manufacturer or sponsor.1 Typically, 
it is used for new pharmaceutical products close 
to launch. The principal evidence for an STA is 
derived from a submission by the manufacturer/
sponsor of the technology. In addition, a report 
reviewing the evidence submission is submitted 
by the evidence review group (ERG), an external 
organisation independent of NICE. This paper 
presents a summary of the ERG report2 for the STA 
of the clinical and cost-effectiveness of sunitinib for 
gastrointestinal stromal tumours.
Description of the 
underlying health problem
Gastrointestinal stromal tumours (GISTs) represent 
the most common mesenchymal neoplasms of 
the gastrointestinal tract.3,4 GISTs are believed to 
originate from an intestinal pacemaker cell called 
the interstitial cell of Cajal.5 The incidence of GIST 
is estimated at 11–14.5 cases per million per year.6,7 
The most frequent primary sites are gastric (50%) 
and small bowel (25%). Colorectal, oesophageal 
and peritoneal GISTs are less frequent. GIST can 
be diagnosed at any age, with a median age at 
diagnosis of 60 years.8
Estimates vary widely on the incidence of new 
cases of GIST, with figures between 200 and 2000 
quoted9 with an apparent acceptance of an upper 
limit of 240. Approximately half of new cases of 
GIST are likely to be metastatic and/or unresectable 
on first presentation, the prognosis of which is 
poor, with few, if any, people surviving beyond 5 
years in the absence of effective treatment.9
The clinical presentation of GIST is highly variable 
according to site and tumour size.10 GIST often 
remains clinically silent until tumours reach a large 
size, when mass effects, bleeding or rupture may 
ensue.11 
Scope of the ERG report
Research question
The research question that Pfizer addressed was: 
‘What is the clinical and cost-effectiveness of 
sunitinib for unresectable and/or metastatic GISTs 
after the failure of imatinib mesylate treatment due 
to resistance or intolerance?’
Intervention
The intervention is a multitargeted tyrosine kinase 
inhibitor produced by Pfizer with the brand name 
of Sutent® and the approved name of sunitinib 
malate.
Outcomes
The outcomes measured for clinical effectiveness 
are overall survival, progression-free survival, time 
to tumour progression, response rates, adverse 
effects of treatment and health-related quality of 
life. Those measured for cost-effectiveness are 
incremental cost per quality-adjusted life-year 
(QALY), incremental cost per life-year gained, Health Technology Assessment 2009; Vol. 13: Suppl. 2
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resource utilisation and the cost of treating adverse 
events.
Type of clinical/cost-
effectiveness data used
In the clinical effectiveness evidence the type of 
data used is ‘time to event’; this is reported as 
median time in weeks with the point estimates 
expressed as hazard ratios and 95% confidence 
intervals. To provide cost-effectiveness evidence 
Pfizer built a Markov model. The model was 
parameterised by effectiveness data and health 
state utilities [derived from the EuroQol 5 
dimensions (EQ-5D) questionnaire] from a 
randomised controlled trial (RCT) by Demetri et 
al.12,13 and longer follow-up unpublished data from 
the same trial. Costs were based on an NHS and 
personal social services perspective.
Stated potential health effects 
Pfizer stated that sunitinib potentially benefits 
patients as a second-line treatment for GIST 
by increasing the time to tumour progression, 
progression-free survival and overall survival 
through inhibiting vascular endothelial growth 
factor/platelet-derived growth factor receptors 
on cancer cells, vascular endothelial cells and 
pericytes, thus constraining the proliferation of 
tumour cells and the development of tumour blood 
vessels. 
Stated costs
Pfizer reported that sunitinib malate is available 
at the following costs: 12.5-mg 28-capsule pack 
= £784.70; 25-mg 28-capsule pack = £1569.40; 
50-mg 28-capsule pack = £3138.80; 12.5-mg 
30-capsule pack = £840.75; 25-mg 30-capsule pack 
= £1681.50; and 50-mg 30-capsule pack = £3363.
Methods 
The ERG report comprised a critical review of the 
evidence for the clinical effectiveness and cost-
effectiveness of the technology based upon the 
manufacturer’s/sponsor’s submission to NICE as 
part of the STA process. 
The manufacturer’s search strategy was reviewed 
by an Information Scientist and the searches 
were rerun with a more extensive RCT filter to 
see if any relevant trials had been omitted. The 
methods used by the manufacturer to report the 
clinical effectiveness were critiqued using the 
principles found in the Centre for Reviews and 
Dissemination’s guidance for undertaking reviews 
in health care.14 We considered Pfizer’s economic 
evaluation against the following study quality 
checklists: NICE reference case,15 Drummond et 
al.16 and Philips et al.17 for decision model-based 
economic evaluations. The model was rerun to 
check for wiring and parameterisation errors.
Results 
Summary of submitted 
clinical evidence
The evidence for this submission is based on one 
RCT12,13 that compares sunitinib with placebo 
for people with unresectable and/or metastatic 
GIST after failure of imatinib due to resistance 
or intolerance and with Eastern Cooperative 
Oncology Group (ECOG) progression status 0–1 
(the most physically able), and one, ongoing, non-
comparative cohort study18 that gives expanded 
access to a similar population but with ECOG 
progression status 0–4. 
The RCT was a double-blind, placebo-controlled, 
parallel-group, multicentre, phase III clinical 
trial. The blinded phase became open-label upon 
disease progression or at the time of interim 
analysis (54 weeks) when patients were allowed to 
cross over from placebo to treatment group.
The results for overall survival are similar in both 
studies with the RCT reporting results for the 
sunitinib arm of 73 median weeks [95% confidence 
interval (CI) 61 to 83 weeks] in comparison to 
75 median weeks 95% CI 68 to 84 weeks] for the 
cohort study. However, the results for time to 
tumour progression in the cohort study (median 
weeks = 41, 95% CI 36 to 47 weeks) are quite 
different from those of the sunitinib arm of the 
RCT (median weeks = 29, 95% CI 22 to 41 weeks). 
These results may be influenced by the different 
ECOG performance status of the two study 
populations and a greater median overall survival 
for the ECOG grade 0–1 in the cohort study [RCT 
73 weeks (95% CI 61 to 83 weeks), cohort 88 weeks 
(95% CI 77 to 97 weeks)].
The interim RCT results for progression-free 
survival showed that those in the sunitinib group 
had a significantly better chance of being alive and 
free from progressive disease than those in the 
placebo group. Median progression-free survival 
with sunitinib was 24.6 weeks (95% CI 12.1 to 28.4 
weeks) compared with 6.4 weeks (95% CI 4.4 to Sunitinib for the treatment of gastrointestinal stromal tumours: a critique of the submission from Pfizer
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10.0 weeks) on placebo (hazard ratio 0.333, 95% CI 
0.238 to 0.467, p < 0.001).
Summary of submitted cost-
effectiveness evidence
The manufacturer used a Markov model, based on 
the renal cell carcinoma (RCC) model developed 
by the Peninsula Technology Assessment Group 
(PenTAG), to model the cost-effectiveness of 
sunitinib compared with best supportive care for 
GIST patients. This had a three-state structure: 
progression-free survival, progressive disease and 
death.
Pfizer’s base-case analysis produced an incremental 
cost-effectiveness ratio (ICER) of £27,365 per 
QALY with the first cycle of sunitinib treatment not 
costed and using effectiveness estimates from their 
rank preserved structural failure time (RPSFT) 
analysis. When we included the cost of the first 
cycle of treatment we estimated that the value of 
the base-case ICER was £32,636 per QALY, again 
using RPSFT effectiveness data. Pfizer’s sensitivity 
analysis produced a range of ICERs from £15,536 
per QALY to £59,002 per QALY. 
When a conventional method of unadjusted 
intention-to-treat (ITT) analysis is used to 
calculate the base-case ICER, values of £93,062 
per QALY (first cycle costed) and £77,107 per 
QALY (first cycle free) are produced. However, this 
method does not account for the overestimated 
effectiveness results in the placebo arm due to 
crossovers; independent expert statistical opinion 
favours the RPSFT method.
Commentary on 
the robustness of 
submitted evidence
Clinical effectiveness
The searches are appropriate and include all 
relevant studies and the RCT is of high quality.
Cost-effectiveness
The approach taken to modelling is reasonable and 
the sources and justification of estimates are also 
generally reasonable.
Weaknesses
The evidence is based on only one completed 
and published RCT. The expanded access cohort 
study is ongoing, is not comparative and is only 
published as an abstract at the time of this report.
The majority of the control population (84%) in the 
RCT crossed over to the intervention group. This 
gave rise to the use of unusual methods of analysis 
(RPSFT) to correct for the bias that this may have 
introduced. Although we believe this to be the 
correct approach we have been unable to check 
that it was applied correctly.
In their economic evaluation, Pfizer have presented 
a miscalculation of cost-effectiveness using the 
ITT overall survival data for best supportive 
care (Kaplan–Meier analysis). The stated ICER 
is £34,649 per QALY when it should have been 
£93,062 per QALY with sunitinib fully costed (or 
£77,107 per QALY if the first cycle of treatment 
is free). (Pfizer corrected this error following 
questions from us.)
A number of errors and omissions were also made 
in the probabilistic sensitivity analysis:
•	 Pfizer used the standard deviation rather than 
the standard error for the utilities
•	 in the model, Pfizer assume a standard 
deviation of 0.02 for progression-free survival, 
whereas the report says 0.20
•	 importantly, Pfizer have not modelled all of 
the uncertainty in the treatment effect for 
progression-free survival and overall survival
•	 there are errors in the Cholesky matrix 
decompositions in modelling the uncertainty 
of the fit of the Weibull curves for treatment 
effectiveness in worksheets ‘PFS’, ‘overall 
survival_RPSFT analysis’ and ‘overall survival_
ITT analysis’. 
Conclusions 
During the blinded phase of the RCT, overall 
survival was significantly longer for those in the 
sunitinib arm than for those who received placebo, 
with a hazard ratio of 0.491 (95% CI 0.290 to 
0.831, p <0.007). However, the ITT analysis of the 
entire study showed that there was no statistically 
significant difference in overall survival for those 
who received sunitinib (73 weeks) compared with 
those who received placebo (65 weeks), with a 
hazard ratio of 0.876 (95% CI 0.679 to 1.129, 
p = 0.306). 
The degree of uncertainty (listed in the next 
section) in the cost-effectiveness analysis means Health Technology Assessment 2009; Vol. 13: Suppl. 2
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that it is not possible to come to firm conclusions 
about the cost-effectiveness of sunitinib for GIST in 
this patient population.
Areas of uncertainty
Given that there are several major errors in the 
probabilistic sensitivity analysis the precise degree 
of uncertainty in the base-case ICER is unknown. 
However, we can say that the uncertainty in the 
base-case ICER (reported as £27,365 per QALY – 
first cycle free) is substantial, given the wide (95%) 
CI for the hazard ratio of overall survival of 0.262 
to 1.234 (using the RPSFT method).
The use of the RPSFT method of analysis has had 
a very large impact on cost-effectiveness; the ICER 
using this method (£32,636 per QALY – first cycle 
costed) is a great deal less than that based on the 
unadjusted ITT data analysis (£93,062 per QALY 
– first cycle costed). Expert statistical advice from 
Ian White (MRC Biostatistics Unit, Cambridge) 
indicates that the RPSFT is the correct method for 
analysis and that it appears to have been correctly 
applied. However, we cannot be sure of this.
We caution that the base-case ICERs may be 
slightly too low as Pfizer’s calculation does not 
include the cost of sunitinib in progressive disease 
for some patients randomised to sunitinib (54 
patients in the sunitinib arm carried on with 
this treatment after disease progression) who 
theoretically may have benefited.
Key issues
The use of the RPSFT method of analysis (instead 
of the conventional approach of censoring 
participants at the point of crossover) greatly 
affects the estimated cost-effectiveness of sunitinib 
for GIST. However, this is a common analysis 
issue in trials of cancer drugs that are found to be 
effective mid-trial, and the use of the RPSFT seems 
appropriate.
The lack of costing of sunitinib in progressive 
disease for patients initially randomised to 
sunitinib does not reflect the treatment of some 
patients in the RCT (22% continued with sunitinib 
after disease progression).
There is a large amount of uncertainty in the 
relative treatment effectiveness for overall survival 
between sunitinib and best supportive care under 
the RPSFT method.
Whether to assume that the first cycle of sunitinib is 
free to the NHS.
Patients in the expanded access cohort study had 
a longer median time to tumour progression than 
those in the RCT.
Summary of NICE guidance 
issued as a result of the STA 
The Appraisal Consultation Document has yet to 
be issued by NICE.
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Feedback
The HTA programme and the authors would like to know 
your views about this report.
The Correspondence Page on the HTA website 
(www.hta.ac.uk) is a convenient way to publish  
your comments. If you prefer, you can send your comments  
to the address below, telling us whether you would like  
us to transfer them to the website.
We look forward to hearing from you.